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The N-terminal Domain of the Y-box Binding Protein YB-1 Plays a Major Role in
Cell Proliferation and Apoptosis
Abstract
Y-box binding protein, YB-1, is a member of the cold shock domain superfamily of proteins. It is involved
in a plethora of cellular functions, including cell proliferation. The molecular mechanisms governing the
involvement of YB-1 in cell proliferation are still unclear. Earlier studies done in chicken pre-B lymphocyte
DT-40 cells in our laboratory have shown that a targeted disruption in one allele of chicken YB-1
(Chk-Yb-1b) gene at its N-terminal domain resulted in multiple abnormalities in the heterozygous mutants,
including slower growth rate, abnormal cell morphology, increased cell size, increased genomic DNA
content and significant changes in levels of cell cycle specific genes like the cyclin dependent kinase
inhibitor - p21.
The current study is based on the hypothesis that the defects seen in the heterozygous mutant DT-40
cells were due to a dominant negative effect of the potential YB-1 N-terminal truncated protein. The goal
of this study is to determine if the introduction of the N-terminal region of YB-1 mimics the defects seen
in the mutant DT-40 cells and to identify cell cycle specific proteins that interact with YB-1.
Using rat hepatoma cells (H411E) as a model system, we introduced three different YB-1 N-terminal
fusion proteins, i) APYB77GFP, the 77 amino acid long full length YB-1 N-terminal sequence containing
clone, ii) APYB36GFP, the 36 amino acid long peptide with the internal deletion Δ12-52
(APYB36Δ12-52GFP represented as APYB36GFP) and iii) APYB26GFP, the 26 amino acid proline rich YB-1
N-terminal sequence containing clone and investigated their effects on incubated cells. Our findings show
that introduction of the APYB26GFP and APYB77GFP proteins resulted in cell cycle arrest at the G2/M
phase. In contrast, incubation with the APYB36GFP protein showed a lower proportion of G2/M phase
cells. APYB26GFP and APYB77GFP protein incubations also resulted in significant apoptosis, which was
confirmed by Annexin V staining, DNA fragmentation analysis and nuclear breakdown analysis. The
APYB36GFP incubation showed lesser percentage of apoptotic cells. We conclude that the YB-1 aminoend sequence plays an important role in cell proliferation and apoptosis.
We also demonstrate that YB-1 interacts with the cell cycle protein - cyclin D1, predominantly in the
cytoplasm of G2/M phase blocked cells and the YB-1 N-terminus is involved in this interaction. We
propose that the proline alanine rich PPAAPPAAPALSAADTK sequence present in APYB26GFP and
APYB77GFP, but not in APYB36GFP is involved in this interaction, as cyclin D1 did not immunoprecipitate
with APYB36GFP. We conclude that the YB-1 N-terminus interacts with Cyclin D1 in the cytoplasm of G2/
M phase cells and this interaction probably sequesters the cyclin D1 in the cytoplasm leading to cell cycle
arrest and apoptosis.
In summary, this study demonstrates that the amino-end domain of YB-1 plays a role in cell proliferation
and apoptosis probably by sequestering cyclin D1 in the cell cytoplasm. It is likely that this process is
mediated through the proline alanine rich sequence PPAAPPAAPALSAADTK, present in the N-terminus of
YB-1.
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Abstract
Y-box binding protein, YB-1, is a member of the cold shock domain superfamily
of proteins. It is involved in a plethora of cellular functions, including cell proliferation.
The molecular mechanisms governing the involvement of YB-1 in cell proliferation are
still unclear. Earlier studies done in chicken pre-B lymphocyte DT-40 cells in our
laboratory have shown that a targeted disruption in one allele of chicken YB-1
(Chk-Yb-1b) gene at its N-terminal domain resulted in multiple abnormalities in the
heterozygous mutants, including slower growth rate, abnormal cell morphology,
increased cell size, increased genomic DNA content and significant changes in levels of
cell cycle specific genes like the cyclin dependent kinase inhibitor - p21.
The current study is based on the hypothesis that the defects seen in the
heterozygous mutant DT-40 cells were due to a dominant negative effect of the potential
YB-1 N-terminal truncated protein. The goal of this study is to determine if the
introduction of the N-terminal region of YB-1 mimics the defects seen in the mutant
DT-40 cells and to identify cell cycle specific proteins that interact with YB-1.
Using rat hepatoma cells (H411E) as a model system, we introduced three different
YB-1 N-terminal fusion proteins, i) APYB77GFP, the 77 amino acid long full length
YB-1 N-terminal sequence containing clone, ii) APYB36GFP, the 36 amino acid long
peptide with the internal deletion Δ12-52 (APYB36Δ12-52GFP represented as
APYB36GFP) and iii) APYB26GFP, the 26 amino acid proline rich YB-1 N-terminal
sequence containing clone and investigated their effects on incubated cells. Our findings
show that introduction of the APYB26GFP and APYB77GFP proteins resulted in cell
cycle arrest at the G2/M phase. In contrast, incubation with the APYB36GFP protein
showed a lower proportion of G2/M phase cells. APYB26GFP and APYB77GFP protein
incubations also resulted in significant apoptosis, which was confirmed by Annexin V
staining, DNA fragmentation analysis and nuclear breakdown analysis. The
APYB36GFP incubation showed lesser percentage of apoptotic cells. We conclude that
the YB-1 amino-end sequence plays an important role in cell proliferation and apoptosis.
We also demonstrate that YB-1 interacts with the cell cycle protein - cyclin D1,
predominantly in the cytoplasm of G2/M phase blocked cells and the YB-1 N-terminus is
involved in this interaction. We propose that the proline alanine rich
PPAAPPAAPALSAADTK sequence present in APYB26GFP and APYB77GFP, but not
in APYB36GFP is involved in this interaction, as cyclin D1 did not immunoprecipitate
with APYB36GFP. We conclude that the YB-1 N-terminus interacts with Cyclin D1 in
the cytoplasm of G2/M phase cells and this interaction probably sequesters the cyclin D1
in the cytoplasm leading to cell cycle arrest and apoptosis.
In summary, this study demonstrates that the amino-end domain of YB-1 plays a
role in cell proliferation and apoptosis probably by sequestering cyclin D1 in the cell
cytoplasm. It is likely that this process is mediated through the proline alanine rich
sequence PPAAPPAAPALSAADTK, present in the N-terminus of YB-1.
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Chapter 1. Introduction
All living organisms must adapt to changes in the environment. One of the most
primitive forms of environmental change that an organism can be exposed to is a change
in temperature. All organisms have developed various essential adaptive mechanisms to
survive within a wide range of temperature stresses (Thieringer et al., 1998). The cellular
response to the temperature stress is represented at the molecular level by the synthesis of
heat-shock or cold-shock proteins. Heat shock proteins are found in bacteria, yeast, plants
and animals. They generally function as molecular chaperones or proteases and their
structure and functions are conserved in all organisms (Lindquist, 1986). In contrast, cold
shock proteins or cold induced proteins found in bacteria function as RNA chaperones
(Matsumoto et al., 1998).
The nucleic acid binding region present in eukaryotic cold shock proteins is
homologous to the bacterial cold shock proteins (Csps). Therefore, proteins having the
nucleic acid binding region belong to the cold shock domain (CSD) superfamily. Y-box
binding proteins which bind to the inverted CCAAT box on gene promoters belong to the
cold shock domain superfamily of proteins. CSD proteins have not been reported in yeast
as yet. All proteins in the CSD family contain a N-terminal and a C-terminal domain,
which are thought to have been added during evolution from unicellular to multicellular
organisms.
1.1 Y-box proteins
The Y-box family of proteins is perhaps the family of most evolutionarily
conserved nucleic acid binding proteins from plants to vertebrates. But the structure of
the N and C-terminal domains of various Y-box proteins vary significantly. These
alterations might have been necessary for the evolution from poikilotherms to
homiotherms and may be involved in its multiple functions. The Y-box proteins were
first identified and isolated by binding to a DNA probe containing the Y-box sequence
5'-CTGATTGGCCAA-3' (Dorn et al., 1987). The cloning and characterization of the
Y-box transcription factor from Xenopus laevis encoded sequence specific DNA binding
domains called FRGY1 and FRGY2 (Murray et al., 1992). These sequences were found
in oocytes, embryos and adult tissues (Tafuri et al., 1990). The cDNA clone for the
CCAAT transcription factor EF1A also revealed novel structural motifs containing
alternative stretches of positively and negatively charged amino acids (Ozer et al., 1990).
Proteins of this family are active as transcriptional and translational regulators for a
wide array of genes containing the Y-box sequence in their promoters (Ladomery, 1997)
and for messenger RNA. Initial studies suggested that binding of the Y-box proteins to
the intact Y-box sequence involves specific interactions (Didier et al., 1988). Later,
binding studies showed that Y-box proteins can bind to a wide range of nucleic acids, like
single stranded DNA (ssDNA), damaged DNA and even triple stranded DNA and RNA
(Horwitz et al., 1994; Koike et al., 1997). Y-box proteins have a special preference for
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binding ssDNA, especially when it contains the Y-box sequence (Tafuri et al., 1992).
They also show a preference for binding pyramidine rich DNA sequences (Wolffe, 1994).
1.2 YB-1 gene family
Y-box binding protein YB-1 is a member of the Y-box protein family. It was first
named in 1988 with reference to the transcription factors binding to the Y-box of MHC
class II promoters (Didier et al., 1988). YB-1 protein was also found to interact with the
HER-2 promoter and EGFR enhancer around the same time (Sakura et al., 1988). It binds
to an inverted CCAAT box (Y-box) repeat within the consensus sequence
5'-CTGATTGG-3', present in the promoter region of the genes it regulates (Ladomery,
1997).
The human YB-1 cDNA was first isolated by screening a human lymphoblastoid
cell cDNA library expressed in Escherichia coli with an oligodeoxynucleotide containing
the Y-box sequence (Didier et al., 1988). In due course, additional Y-box binding
proteins were identified in frogs (Tafuri et al., 1990), rats (Ozer et al, 1990), mice (Tafuri
et al., 1993) and chickens (Grant et al., 1993; Kandala and Guntaka, 1994). A number of
genes closely related to YB-1 have also been identified, including dbpA cloned in 1995
(Kudo et al., 1995) and contrin or dbpC cloned in 1999 (Tekur et al., 1999). Comparison
of characteristics of these genes is shown in Table 1.1. YB-1 is identical to dbpB. Several
eukaryotic genes including genes encoding major histocompatibility class II antigens,
thymidine kinase, proliferating cell nuclear antigen, DNA polymerase α, epidermal
growth factor receptor, DNA topoisomerase IIα and multidrug resistance I protein
contain the Y-box binding consensus sequence in their regulatory regions (Wolffe et al.,
1992 and 1994; Ladomery et al., 1995).
YB-1 gene is comprised of 8 exons and 7 introns spanning 19 kb of genomic DNA
and is located on chromosome 1 p 34 (Toh et al., 1998). All introns are flanked by the
dinucleotides GT and AG, consistent with the eukaryotic gene sequences for splice
junctions in eukaryotic genes (Breathnach et al., 1981). The YB-1 mRNA is
approximately 1.5 kb long and codes for a 324 amino acid protein with a predicted mass
of 43 kDa. YB-1 CSD is encoded by exons 1-5 and C-terminal domain by exons 6-8.
Sequence diversity among different YB-1 cDNA clones has also been described (Kolluri
et al., 1991).
1.2.1 Cellular expression of YB-1
YB-1 is induced in various cell types in response to mitogenic stimuli, such as
cytokine stimulated T-cells (Sabath et al., 1990), serum activated fibroblasts (Ito et al.,
1994) and agonist stimulated endothelial cells (Stenina et al., 2000). It is ubiquitously
expressed, especially in skeletal muscles, kidney, lungs and liver. Actively proliferating
cells/tissues like early chicken and rat embryos (Grant et al., 1993; Ito et al., 1994),
wound healing cells in regenerating liver tissue following chemical induced damage
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Table 1.1 Comparison of dbpA, dbpB/YB-1 and dbpC
Name Chromosome Gene (kbp) No. of exons Amino Acids Expression
dbpA

12p13

24

10

372

Heart, Muscle

dbpB/YB-1

1p34

19

8

324

Ubiquitous

dbpC

17p11

6

9

364

Germ cell

Comparison of characteristics of the members of the human Y-box protein family.
(Adapted with permission. Kohno, K., Izumi, H., Uchiumi, T., Ashizuka, M., and
Kuwano, M. (2003) The pleiotropic functions of the Y-box-binding protein, YB-1.
Bioessays. 25, 691-698.)
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(Grant et al., 1993), or hepatectomy (Ito et al., 1994), colorectal epithelial glands (Shibao
et al., 1999) and various cancer cells (Ohga et al., 1996) show higher expression of YB-1
as compared to quiescent/adult differentiated cells.
1.2.2 Cellular localization of YB-1
YB-1 is a major structural component of messenger ribonucleoprotein (mRNP)
complexes in the cells. It is predominantly present in the cell cytoplasm. It is translocated
to the nucleus under conditions like U.V. irradiation (Koike et al., 1997), hyperthermia
(Stein et al., 2001), IF-γ treatment (Higashi et al., 2003), adenovirus infection (Holm et
al., 2002; Paranjape et al., 2007), along with splicing factor SRp30c (Raffetseder et al.,
2003) and under high levels of ectopic YB-1 expression (Zhang et al., 2006). Both the
CSD and CT domains of YB-1 are implicated in its nuclear localization. The CT domain
consists of a non-canonical nuclear localization signal and the CSD is shown to
contribute to the nuclear retention (Bader et al., 2005). However the CT domain can also
bind to a yet unknown anchoring protein in the cytoplasm and thus retain the YB-1 there
(Koike et al., 1997). YB-1 is also shown to associate with nascent transcripts cotranscriptionally and is presumed to accompany mRNA into the cytoplasm (Soop et al.,
2003).
1.3 Architecture and domains of YB-1
The vertebrate Y-box proteins are comprised of three domains, the variable amino
or N-terminal domain, a highly conserved nucleic acid binding domain or the cold shock
domain (CSD) and a carboxyl or C-terminal domain (Wolffe et al., 1994; Graumann et
al., 1998). A comparison of the three well-characterized Y-box proteins is shown in Fig.
1.1.
1.3.1 Amino terminal domain
The YB-1 N-terminal domain is rich in amino acids alanine and proline.
Functionally, the YB-1 N-terminal domain has not been very well defined, though it is
thought to be a trans-activation/regulation domain (Tafuri et al., 1992; Wolffe, A.P.,
1994; Kohno et al., 2003). YB-1 also binds to some proteins through its N-terminal
domain, for example, p53 (Okamoto et al., 2000).
1.3.2 Cold shock/nucleic acid binding domain
The YB-1 CSD domain, consisting of approximately 80 amino acids, is one of the
most evolutionary conserved domains from bacteria to eukaryotes (Wolffe et al., 1992;
Wolffe, 1994; Ladomery et al., 1995). It shows 93% sequence identity within the family
of Y-box proteins (Wolffe, 1994). Structurally, it is comprised of a five-stranded β-barrel
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Fig. 1.1 Schematic representation of the amino acid alignment of dbpA, dbpB/YB-1
and dbpC
This figure depicts the organization of domains of three members in the CSD superfamily
of proteins. A/P indicates the alanine and proline rich N-terminal domain and B/A repeat
indicates the basic and acidic amino acid clusters in the C-terminal domain. (Adapted
with permission. Kohno, K., Izumi, H., Uchiumi, T., Ashizuka, M., and Kuwano, M.
(2003) The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays. 25, 691698.)
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(Wistow et al., 1990) containing RNP-1 and RNP-2 like consensus motifs (Landsman,
1992) and belongs to the β-sheet RNA-binding protein group (Graumann et al., 1996).
The CSD domain is involved in binding to DNA and RNA (Wolffe et al., 1992 and
1994; Schindelin et al., 1994; Bouvet et al., 1995). It is also involved in specific (Bouvet
et al., 1995) and non-specific RNA binding (Tafuri et al., 1993) and in specific ssDNA
binding (Tafuri et al., 1992). The non-specific RNA binding occurs during packaging of
mRNA in maturing germ cells. The specific RNA binding takes place in the nucleation
process during the assembly of mRNP particles (Wolffe et al., 1994; Bouvet et al., 1995).
The specific ssDNA binding is required for the binding of YB-1 to specific single
stranded parts of promoters, which thereby affect the binding of other transcription
factors and induce transcription (MacDonald et al., 1995; Swamynathan et al., 1998).
1.3.3 Carboxy terminal domain
The YB-1 C-terminal domain consists of alternating clusters of about 30 acidic and
basic amino acids, referred to as B/A islands (Murray et al., 1992). Structurally, the
acidic regions separating the B/A islands are predicted to form alpha helices. The B/A
repeats may be a structure unique to vertebrate organisms, since plants and invertebrates
show zinc finger motifs.
The YB-1 C-terminal domain binds DNA and RNA in a sequence-independent
manner (Izumi et al., 2001). The structure of this domain helps it function as a charged
zipper, facilitates dimer formation (Tafuri et al, 1992) and is essential for the formation of
messenger ribonucleoprotein (mRNP) particles in which mRNA is stored (Matsumoto et
al., 1996). The C-terminal domain is also thought to be involved in protein-protein
interactions (Bouvet et al., 1995).
1.4 Regulation of transcription and translation of YB-1
The levels of YB-1 protein have to be precisely regulated for cells to function
normally. YB-1 production is regulated both at transcriptional and posttranscriptional/translational levels. YB-1 gene promoter has multiple E-boxes and
GC-boxes (Makino et al., 1996). Transcription of YB-1 gene is stimulated by the tumor
suppressor gene product, p73, through an enhanced recruitment of the c-Myc-Max
complexes to the E-Box sequences (Uramoto et al., 2002). YB-1 mRNA shows
regulation by its own product. YB-1 protein represses translation of YB-1 mRNA by
binding to specific elements in the 5′ and 3′ untranslated regions (Fukuda et al., 2004;
Skabkina et al., 2005). YB-1 protein is negatively regulated by F-Box protein 33
(FBX33), which targets the YB-1 protein for polyubiquitination and proteosomal
degradation (Lutz et al., 2006).
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1.5 Interaction of YB-1 with other cellular proteins
YB-1 interacts with a diverse range of proteins, which are shown in Fig. 1.2. It
interacts with other transcription factors like p53 (Okamoto et al., 2000), NFκB sub unit
Rel A or p65 (Raj et al., 1996), AP-2 (Mertens et al., 2002), multivalent zinc finger factor
- CTCF (Chernukhin et al., 2000), TBP (Shnyreva et al., 2000), Smad3 (Higashi et al.,
2003) and YY-1 (Matsumoto et al., 2005). It also shows interaction with some RNA
binding proteins like EWS (Chansky et al., 2001), AUF-1 (Moraes et al., 2003), Poly (C)binding protein (Funke et al., 1996), SRp30 (Raffetseder et al., 2003), exuperantia
(Wilhelm et al., 2000), iron responsive element binding protein-2 or IRP2 and hnRNPK
(Ashizuka et al., 2002; Shnyreva et al., 2000) and YBAP1 (Matsumoto et al., 2005). Cell
cycle proteins like Cdk4 (Balda et al., 2003) and Cdk5 (Moorthamer et al., 1999), repair
proteins like proliferating cell nuclear antigen - PCNA (Ise et al., 1999) and human
endonuclease III (Marenstein et al., 1999) also interact with YB-1. Among the other
protein physical partners of YB-1 are viral proteins like human immunodeficiency type 1
tat protein (Ansari et al., 1999), TAR RNA molecules and human polyoma JC virus large
T antigen (Safak et al., 1999). YB-1 also interacts with the proteins ZO-1 (Balda et al.,
2000), RalA (Frankel et al., 2005), Pur-α (Safak et al., 1999), DNA binding protein A
and cardiac ankyrin repeat protein - CARP (Zou et al., 1997) and actin filaments
(Ruzanov et al., 1999). These interactions indicate the complexity involved in the
expression of pleiotropic functions of YB-1. Further characterization of these interactions
will aid in a better understanding of the different integrated functions of YB-1.
1.6 Functions of YB-1
Y-box binding protein YB-1 is a multifunctional DNA/RNA binding protein,
which is involved in reproduction, storing and expression of genetic information. It is
shown to have a role in varied cellular functions like transcription and translation
regulation, DNA repair, drug resistance, stress response and regulation and cell
proliferation.
1.6.1 Transcriptional regulation
YB-1 controls the transcription of various eukaryotic genes involved in different
cellular functions, especially cell proliferation and DNA repair. Transcription regulation
by YB-1 can be classified into three main categories.
YB-1 can bind directly to the Y-box or related sequences in the promoter regions
of many genes and regulate transcription. For example, YB-1 was shown to directly bind
to the Y-box motif in cyclin A promoter and to the proximal and distal CCAAT boxes in
cyclin B1 promoter by electrophoretic mobility shift assay. Using reporter gene construct
analysis, this binding was shown to directly regulate the transcription of both the cyclin
genes (Jurchott et al., 2003). Similarly transcription regulation is seen, by the direct
binding of YB-1 to the Y-box in promoter regions of genes like MDR1 (Swamynathan et
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Fig. 1.2 Schematic representation of some of the YB-1 protein interacting partners
and the domain of YB-1 involved in this interaction
This is a non-exhaustive representation of interaction of YB-1 with other proteins. YB-1
is shown to interact with a multitude of proteins through one or more domains; for
example, it interacts with p53 through all three domains, whereas only the C-terminal
domain mediates its interaction with PCNA.
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al., 1998), human major vault protein (MVP) or the lung resistance related protein (LRP)
(Stein et al., 2005), myosin light-chain 2v (Zou et al., 1995), human α2 collagen (Higashi
et al., 2003) and MMP13 (Samuel et al., 2007).
YB-1 can also regulate gene expression in a Y-box independent manner, via
interaction with other transcriptional factors. For example, co-transfection analysis
showed that YB-1 and Rel A / NF-κB p65 subunit cooperate to synergistically activate
the GM-CSF proximal promoter (Diamond et al., 2001). Similar transcription regulation
is seen in genes like p21 (Okamoto et al., 2000) and grp73 (Li et al., 1997) among others.
YB-1 can also bind to single stranded DNA with high affinity for transcription
regulation. Presence of single stranded DNA has been reported in regions of many
transcriptionally active promoters (Swamynathan et al., 1998; Wilusz et al., 2001). By
radiolabeled single stranded probe analysis YB-1 was shown to bind preferentially to
single stranded components on MMP-2 promoter and by repoter gene constructs this
binding was shown to regulate transcription of the MMP-2 (Mertens et al., 1997). This
mode of transcriptional regulation by YB-1 occurs in other genes also like HIV-1
(Sawaya et al., 1998), Fas/CD95 (Lasham et al., 2000), Rat α 1 procollagen (Dhalla et al.,
1998), rat gelatinase A (Mertens et al., 1999 and 2002), JC polyomavirus late gene (Chen
et al., 1995; Safak et al., 1999), MHC class II genes (MacDonald et al., 1997; Montani et
al., 1998), thyrotropin receptor (Ohmori et al., 1996), mouse α 1 collagen (Norman et al.,
2001), GM-CSF (Coles et al., 2000), VEGF (Coles et al., 2002) and EGFR (Stratford et
al., 2007)
1.6.2 Translational regulation
Translation regulation of genes by YB-1 is mediated by different mechanisms. It
binds with mRNA nuclear precursors and thus participates in alternative splicing of
mRNA (Chansky et al., 2001; Stickeler et al., 2001). In the cytoplasm of cells, YB-1
serves as the main mRNA packaging protein (Skabkin et al., 2004) where it regulates the
lifetime (Evdokimova et al., 2001) and mRNA template activity in protein synthesis
(Minich et al., 1992; Sommerville et al., 1999; Evdokimova et al., 1999). It has been
shown to have a dual effect on protein synthesis. At low ratios typical for polysomal
mRNPs, YB-1 stimulates translation at the stage of initiation (Minich et al., 1992;
Evdokimova et al., 1998; Pisarev et al., 2002). At an increased ratio corresponding to free
mRNPs, YB-1 inhibits the protein synthesis both in vitro (Minich et al., 1992; Nekrasov
et al., 2003) and in vivo (Davydova et al., 1997) at the very beginning of translation
initiation, by displacing the translation initiation factor eIF4G from mRNA (Nekrasov et
al., 2003). Sequence specific RNA binding of YB-1 has also been shown in vivo (Bouvet
et al., 1995).
YB-1 interacts with glutathione peroxidase transcripts at the seleno-cysteine
insertion sequence located 3' to alternatively read UGA codons (Shen et al., 1998). YB-1
is also one of the first detected RNA binding proteins affecting CD44 alternative splicing
(Stickeler et al., 2001). It interacts with RNA binding protein hnRNPK (Funke et al.,
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1996; Shnyreva et al., 2000) and is also speculated to bind to splicing factor 1 (SF1)
(Stickeler et al., 2001). It is involved in translation regulation of iron-responsive elementbinding protein (IRP-BP/IRP2) (Ashizuka et al., 2002). YB-1 along with another RNA
binding protein, nucleolin, is required for IL2 mRNA stabilization induced by T-cell
activation signals (Chen et al., 2000). It is also involved in translational regulation of
Cyclin D1, c-jun, mertk and PDGFR-β mRNA, by the PI3K-AKT pathway (Evdokimova
et al., 2006). It is shown to be controlling transforming growth factor beta-1 (TGF-β1)
translation in proximal tubular cells (Fraser et al., 2007).
In addition to being responsible for translational regulation of many other
eukaryotic genes, YB-1 is involved in autoregulation of its mRNA (Skabkina et al.,
2005), by binding a regulatory element within the 3′ untranslated region (UTR) of YB-1
mRNA. YB-1 strongly and specifically inhibits its own synthesis at the stage of initiation,
with accumulation of its mRNA in the form of free mRNPs. Poly (A) binding protein
(PABP) competes with YB-1 for binding to the YB-1 mRNA regulatory element and
restores the translational activity of YB-1 mRNA, in a Poly (A) tail independent manner
(Skabkina et al., 2003). Some studies also show that YB-1 protein autoregulates its own
translation by binding to the 5′-UTR of its mRNA (Fukuda et al., 2004).
1.6.3 DNA repair
Numerous studies implicate YB-1 in DNA repair. YB-1, which is expressed
ubiquitously in human tissues at basal levels, is over expressed in human cancer cell lines
that are resistant to cisplatin, where it binds to cisplatin modified DNA (Ohga et al.,
1996). It has also been shown to bind preferentially to apurinic DNA or single stranded
DNA, but not to UV-irradiated DNA, suggesting that it binds preferentially to only
structurally altered DNA (Hasegawa et al., 1991). YB-1 is shown to interact with
proliferating cell nuclear antigen, PCNA and possess a 3′ → 5′ exonuclease activity (Ise
et al., 1999). A yeast two-hybrid system for base excision repair enzymes identified YB-1
interaction with human endonuclease III enzyme and hNth1 (Marenstein et al., 2001).
YB-1 is also shown to be capable of promoting rapid annealing of complementary
nucleic acid strands (Skabkin et al., 2001). It was shown to actively promote strand
separation of duplex DNA containing either mismatches or cisplatin modifications
independently of the nucleotide sequence and also shown to associate directly or
indirectly with DNA repair proteins MSH2, Ku80 and WRN in vitro (Gaudreault et al.,
2004). The preferential binding to structurally altered DNA, its stress inducible nuclear
localization and its ubiquitous distribution within all tissues of higher organisms is
indicative that YB-1 plays an important role in DNA repair mechanism.
1.6.4 Drug resistance
Multiple studies underscore the role of YB-1 in drug resistance. Overexpression of
YB-1 in cancer cells was shown to result in their resistance to etoposide and doxorubicin
(Bargou et al., 1997) indicating that YB-1 might be one of the factors responsible for
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drug resistance. Disruption of YB-1 by the antisense approach resulted in sensitizing the
cells to drugs (Ohga et al., 1996 and 1998), implicating YB-1 specifically for this
function. YB-1 was shown to up regulate the expression of mdr-1, mrp-1 and mvp genes
(Stein et al., 2001 and 2005), which are involved in drug resistance. Expression of mdr-1
gene was shown to result in production of p-glycoprotein, an ABC transporter,
responsible for efflux of chemotherapeutic compounds from cancer cells, thereby
rendering them drug resistant (Choudhuri et al., 2006). Disruption of one allele of YB-1
gene in mouse embryonic stem cells resulted in the mutated cells showing defects in drug
resistance and increased sensitivity to cisplatin and mitomycin C (Shibahara et al., 2004).
1.6.5 Stress response
YB-1 is a nucleocytoplasmic shuttling protein, involved in many DNA and RNA
dependent events. Therefore distribution of YB-1 between nuclear and cytoplasmic
compartments must be stringently controlled. YB-1 is an integral part of the general
stress response signaling pathway required for protecting cells from a variety of stresses.
Nuclear translocation of YB-1 has been shown as a stress response to various
extracellular insults, including adenovirus infection (Holm et al., 2002), UV irradiation
(Koike et al., 1997), hyperthermia (Stein et al., 2001), anti cancer drugs (Uchiumi et al.,
1993) or association with certain proteins such as tumor suppressor p53 and splicing
factor SRp30c (Raffetseder et al., 2002). It was shown that YB-1-/- embryos demonstrate
reduced abilities to respond to oxidative, genotoxic and oncogene induced stresses (Lu et
al., 2005).
1.6.6 Cell proliferation
YB-1 is shown to be involved in cell proliferation both indirectly and directly.
Several studies show that YB-1 protein levels are upregulated in actively proliferating
cells like embryonic and cancer cells as compared to quiescent or non-proliferating cells
(Oda et al., 1998; Shibao et al., 1999; Kamura et al., 1999; Hipfel et al. 2000; Janz et al.,
2002) and regenerating liver tissue following chemical induced damage (Grant et al.,
1993) or hepatectomy (Ito et al., 1994). YB-1 expression is seen throughout development
and its expression levels correlate with the cell proliferative states (Lu et al., 2005). YB-1
is involved in activation of many genes implicated in cell proliferation like thymidine
kinase (Ladomery et al., 1995), growth hormone receptor genes (Swamynathan et al.,
1998), proliferating cell nuclear antigen (PCNA) (Ise et al., 1999; Gu et al., 2001), Cyclin
A and B1 genes (Royer et al., 2003), DNA Polymerase α (En-Nia et al., 2005), PDGF-β
in mesangioproliferative glomerular disease (Mertens et al., 2005) and epidermal growth
factor receptor (Dunn et al., 2007). YB-1 is probably responsible for viral replication of
DNA (Holm et al., 2002). It is reported to be a repressor of cell death associated gene, fas
(Lasham et al., 2000).
YB-1 is overexpressed in malignant tissues of breast cancer patients (Bargou et al.,
1997), non-small cell lung cancer (Shibahara et al., 2001; Gu et al., 2001), ovarian serous
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adenocarcinomas (Kamura et al., 1999), human oseteosarcomas (Oda et al., 1998),
colorectal carcinomas (Shibao et al., 1999) synovial sarcoma (Oda et al., 1999) and
malignant melanomas (Hipfel et al., 2000). Diffuse expression of YB-1 is seen in
dysplasia-associated lesions or masses of ulcerative colitis, both of which are associated
with a high risk of cancer (Fogt et al., 2001). Presence of YB-1 can identify high-risk
patients in both the presence and absence of post chemotherapy and independently known
tumor biologic factors (Janz et al., 2002). It was also shown that YB-1 promotes breast
cancer through induction of chromosomal instability that emerges from mitotic failure
and centrosome amplification (Bergmann et al., 2005).
YB-1 has also been shown to be involved in cell proliferation by disruption of its
alleles resulting in a reduction in growth. Disruption of both alleles of chicken YB-1 gene
at the cold shock domain in DT-40 cells caused a slow growth phenotype in YB-1 -/- cells
(Matsumoto et al., 2005). A homozygous null mice with a true null mutation of YB-1
exhibited severe growth retardation and progressive mortality of YB-1-/- embryos after
E13.5 (Lu et al., 2005). YB1-/- fibroblasts from a double knock out mouse showed greatly
reduced cell proliferation and altered cell morphology, demonstrating the critical role
played by YB-1 in cell proliferation (Uchiumi et al., 2006). Downregulation of YB-1 by
shRNA was shown to result in significant reduction in rate of proliferation and increased
rate of apoptotic cell death (Schittek et al., 2007).
1.7 Previous Research
1.7.1 Introduction
The precise modification of chromosomal sequences by targeted integration of
artificial constructs provides a powerful approach to determine the function of genes and
regulatory elements within a living cell. In the last few years, many studies have been
done to study the role of YB-1 in cell proliferation, by knocking down one or both alleles
of the gene in different systems. One of the very first of such studies was reported by our
laboratory in 2002 (Swamynathan et al., 2002). This study involved the disruption of one
allele of chicken YB-1 gene in DT-40 cells and investigation of the defects seen in the
heterozygous mutants.
DT-40 is a chicken pre-B lymphocyte cell line, which allows efficient gene
disruption due to its high homologous recombination activity (Buerstedde et al., 2002).
It has been proven to be a cell line popular in the study of cell autonomous (Nakayama et
al., 2001; Um et al., 2001; Takata et al., 2001), targeted disruption of a number of genes
(Takeda et al., 1992; Wang et al., 1996; Takami et al., 1997) and B-cell specific
processes (Bezzubova et al., 1997; Kurosaki et al., 1997), due to high ratios of targeted to
random integration of transfected constructs (Buerstedde et al., 1991).
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1.7.2 Strategy used for disruption of one allele of Chk-Yb-1b gene
A neomycin resistance gene, NeoR, under the control of SV40 promoter/enhancer
was introduced into the Chk-YB-1b gene in DT-40 cells, in order to replace a 400 bp StyI
fragment overlapping the first exon-intron region, by homozygous recombination (Fig.
1.3). This resulted in a disruption of one of the alleles, which was confirmed by Southern
blotting and PCR amplification experiments.
Due to this disruption in one allele, normal splicing and formation of full length
mRNA is expected of only one allele, whereas the disrupted allele is expected to undergo
defective splicing, leading to the final formation of one copy of normal mRNA and one
copy of disrupted mRNA and their respective proteins (Fig. 1.4).
1.7.3 Defects seen in the heterozygous mutant DT-40 cells
Numerous defects were detected in the heterozygous mutant DT40 cells. One of
the most interesting defects seen was a defective cell cycle. When DNA content of the
wild type and mutant DT-40 cells was analyzed by FACS analysis, a large proportion of
the mutant cells showed 4n DNA in contrast to the wild type cells with 2n DNA (Fig.
1.5A). This suggests that the cell cycle defect in mutant cells is past the DNA synthesis or
S-phase of cell cycle. Approximately 25-30% of the cells also showed about 6n or greater
content of DNA, indicating re-replication of DNA without cell division. This result
strongly suggests that the defect in cell cycle is very likely at the G2/M phase.
DT40YB-1b +/- cells were also found to grow slowly, with a doubling time of more
than 36-40 hrs. when compared to the 12-14 hrs. for wild type cells (Fig. 1.5B). This
indicates that disruption of one allele of YB-1 has a marked effect on cell proliferation.
Some morphological abnormalities were also detected in the heterozygous mutants. In
contrast to wild type DT-40 cells, which were small and well rounded with a smooth
surface, the mutant cells showed a larger (1.5-2 times), irregular appearance with hairy
projections from the rough cell surface (Fig. 1.5C).
Heterozygous mutant DT-40 cells also showed some evidences of apoptosis.
Condensed chromatin with distinct sub-nuclear fragments, which is a hallmark of
apoptotic cells, was detected in case of DT40YB-1b +/- cells, by cellular staining with
Hoechst 33258 vital dye (Fig. 1.5D), whereas the nuclei of wild type cells stained
uniformly. Fragmentation of DNA in the form of multimers of nucleosome length DNA
was also seen in the mutant cells, but not in wild type cells (Fig. 1.5E), clearly indicating
that the mutant cells underwent apoptosis.
DNA microanalysis of 120 cell cycle related genes in DT40YB-1b +/- cells showed
that there was a downregulation of genes for cyclin dependent kinase inhibitor p21,
replication factor C 40 protein, MM-1, MAPKK1, GADD153 and C-jun N-terminal
kinase 3 α2. Enhanced expression of Ser/Thr protein kinase, replication factor C 37,
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Fig. 1.3 Schematic representation of disruption of one allele of YB-1 gene
The targeted disruption of one allele of Chk-YB-1b gene at its N-terminal Sty I site
resulted in one copy of wild type YB-1 protein and a potentially truncated protein
spanning the YB-1 N-terminus up to the Sty I site.

Fig. 1.4 Schematic representation of splicing of the two alleles of Chk-YB-1 gene
after the disruption of one allele
After the targeted disruption of one allele of chicken YB-1 gene, normal splicing and
formation of full length mRNA is expected of only the wild type allele, whereas the
disrupted allele is expected to undergo defective splicing, leading to the final formation
of one copy of normal mRNA and one copy of disrupted mRNA and their respective
proteins.
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Fig. 1.5 Defects seen in the heterozygous mutant DT-40 cells
A) FACS analysis of wild type and mutant DT-40 cells stained with propidium iodide
shows increased genomic DNA content in the heterozygous mutant DT-40 cells.
B) Growth curve of wild type and mutant DT-40 cells shows that the doubling time of the
mutant cells was 3-4 times higher than the wild type cells.
C) Morphological defects were seen in the mutant DT-40 cells, which were large,
irregular and rough surfaced, in comparison with the wild type cells, which are small and
spherical with smooth edges.
D) Evidence in the form of chromatin condensation is seen in the mutant DT-40 cells
stained with the vital dye, Hoechst 33258, as compared to the wild type cells.
E) DNA fragmentation (fragments of multimers of unit nucleosomal size DNA) was seen
only in case of the mutant DT-40 cell DNA, but not in the wild type cell DNA.
F) Microarray analysis of 120 genes in the mutant and wild type cells revealed that some
genes are upregulated or downregulated in the mutant cells when compared to the wild
type cells. Genes showing significant levels of differences are shown in this figure.
(Reprinted with permission. Swamynathan, S.K, Varma, B.R., Weber, K.T., and
Guntaka, R.V. (2002) Targeted disruption of one allele of the Y-box protein gene, ChkYB-1b, in DT40 cells results in major defects in cell cycle. Biochem Biophys Res
Commun. 296, 451-457.)

15

A

C

E

B

D

F

16

ubiquitin conjugated enzyme E2, UV excision repair protein, RAD23A and tubulin α1subunit genes was seen (Fig. 1.5F).
1.8 Hypothesis
Equal amounts of YB-1 full length mRNA and protein were seen to be present in
both the wild type and heterozygous mutant DT-40 cells. Therefore the abnormalities
seen cannot be attributed to the decrease of full length YB-1 protein in mutant cells. Our
hypothesis is that altered phenotype of mutant DT-40 cells could be due to a dominant
negative effect, exerted by a potential truncated protein spanning the N-terminus of YB-1
up to the Sty I site at the amino acid 77, encoded by the disrupted allele. If so,
introduction of the exogenous fusion protein carrying the N-terminal sequence of YB-1
should mimic the phenotypic changes.
DT40YB-1b +/- cells also showed a change in expression of a few cell cycle related
genes, including the cyclin dependent kinase inhibitor, p21. We propose the possibility of
YB-1 interacting with some of these cell cycle proteins at a protein level, especially at the
G2/M phase, since the defects seen in the mutant DT-40 cells were most likely at the
G2/M phase of cell cycle.
1.9 Significance of this study
In the past couple of years, there has been a rapid progress in understanding the
function of YB-1. However current knowledge about the molecular mechanisms
underlying the role of various domains of YB-1 in cell proliferation is limited. The first
part of this project involves study of the effects of introduction of YB-1 N-terminal
protein into mammalian cells. The experiments are designed to investigate if the
introduction of YB-1 N-terminal protein results in an effect on the cell cycle and cell
survival of the mammalian cells. Our results demonstrate that the YB-1 amino end
protein internalization results in cell cycle arrest at the G2/M phase and apoptosis. In
order to understand the integrated functions of YB-1, it is essential to study all its
molecular interactions with the other proteins. The second part of this project is designed
to investigate the interaction of YB-1 with the cell cycle protein, cyclin D1. The results
indicated that full length YB-1 interacts and co-localizes with cyclin D1 at the G2/M
phase of cell cycle predominantly in the cytoplasm of mammalian cells. The YB-1
N-terminal protein is also able to interact with the cyclin D1 in the cytoplasm of
nocodazole-blocked cells.
Overall this analysis of YB-1 has provided an important insight into its role in cell
proliferation and in oncogenesis. Furthermore, understanding this YB-1 interaction with
cyclin D1 may offer novel strategies for the development of unique anti-cancer drugs.

17

Chapter 2. YB-1 Amino Terminal Domain Plays a Major Role in Cell Proliferation
and Apoptosis
2.1 Introduction
YB-1 is a multifunctional protein, involved in a multitude of important cellular
functions, including cell proliferation. Numerous studies demonstrate a role of YB-1 in
cell proliferation. YB-1 protein levels are upregulated in actively proliferating cells like
embryonic and cancer cells as compared to quiescent or non-proliferating cells (Oda et
al., 1998; Shibao et al., 1999; Kamura et al., 1999; Hipfel et al. 2000; Janz et al., 2002)
and regenerating liver tissue following chemical induced damage (Grant et al., 1993) or
hepatectomy (Ito et al., 1994). YB-1 expression is seen throughout development and its
expression levels correlate with the cell proliferative states (Lu et al., 2005), for example,
expression of YB-1 in multiple myeloma cells is associated with a highly proliferative
phenotype (Chatterjee et al., 2007). YB-1 is also involved in activation of many genes
implicated in cell proliferation like thymidine kinase (Ladomery et al., 1995), growth
hormone receptor genes (Swamynathan et al., 1998), proliferating cell nuclear antigen
(PCNA) (Ise et al., 1999; Gu et al., 2001), Cyclin A and B1 genes (Royer et al., 2003),
DNA Polymerase α (En-Nia et al., 2005), PDGF-β in mesangioproliferative glomerular
disease (Mertens et al., 2005) and epidermal growth factor receptor (Dunn et al., 2007).
In order to gain a better insight into the role of YB-1 in cell proliferation, studies
have been done by knocking out one or both alleles of YB-1. One of the very first of a
series of such studies published by our laboratory showed that a targeted disruption of
one allele of chicken YB-1 gene in DT40 cells at the amino terminal domain, resulted in
major cell cycle defects like increased doubling time, increased genomic DNA content,
increased cell size and apoptosis in a fraction of the cell population (Swamynathan et al.,
2002). In contrast, targeted disruption of one allele of YB-1 gene at the carboxy terminal
domain in mouse embryonic stem cells resulted in no apparent growth defects in the
mutated cells (Shibahara et al., 2004). However the mutated cells exhibited defects in
drug resistance and sensitivity to cisplatin and mitomycin C. Another study involving the
disruption of both alleles of chicken YB-1 gene at the cold shock domain in DT-40 cells,
demonstrated a slow growth phenotype in YB-1 -/- cells but no apparent growth defect in
heterozygous mutants with one YB-1 disrupted allele (Matsumoto et al., 2005). The
mutant cells showed major translational defects. A comparison of these studies (Fig. 2.1)
shows the disruption of each domain of YB-1, either on one or both alleles of the gene,
resulting in defects in different functions, suggests that each domain is involved in some
specific cellular functions.
A non-redundant role of YB-1 in cell proliferation and growth was suggested by
creating homozygous mice with a true null mutation in the YB-1 gene (Lu et al., 2005).
This study showed that after E13.5, YB-1-/- embryos exhibited severe growth retardation
and progressive mortality. The YB-1-/- fibroblasts demonstrated reduced abilities to
respond to oxidative, genotoxic and oncogene induced stresses. A definitive role for
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Fig. 2.1 Comparison of disruption made in the YB-1 domains by various
investigators and their corresponding defective functions
Arrows indicate a representation of disruptions made in each of the three domains of
YB-1. As seen from the three studies, disruption in each of the domains results in defects
in different functions of YB-1, suggesting a possibility of each of the YB-1 domains
being responsible for those particular functions.

19

YB-1 in cell proliferation has been proven by double knock out mice by disruption of
both alleles of YB-1 leading to embryonic lethality (Uchiumi et al., 2006). Further studies
with YB1-/- fibroblasts showed greatly reduced cell proliferation and altered cell
morphology, demonstrating the critical role played by YB-1 in cell proliferation. Latest
studies showed that downregulation of YB-1 by shRNA results in significant reduction in
rate of proliferation and increased rate of apoptotic cell death (Schittek et al., 2007).
Indepth analysis of the phenotypic abnormalities seen in the heterozygous mutant
DT-40 cells from our study suggested that the N-terminal domain of YB-1 might be
involved in the regulation of cell proliferation by YB-1. We ruled out the possibility of
attributing the defects to a decrease in wild type YB-1 mRNA or protein, since no
reduction in either of their levels was detected. This was most likely due to the tetraploid
phenotype of the DT-40 YB-1 +/- cells. We then speculated that a possible reason for the
altered phenotype could be the dominant negative effect exerted by a potentially
truncated protein encoded by the disrupted allele. Owing to antibody restrictions for a
chicken cell system, detection of a clear band of truncated protein was difficult.
Therefore, testing our hypothesis warranted the use of another cell system and an
exogenous source of the potential truncated protein. If our hypothesis is right,
introduction of the exogenous fusion protein carrying the N-terminal sequence of YB-1
should mimic the phenotypic changes.
The plasma membrane constitutes a lipid bilayer inserted with proteins and
glycoproteins. The hydrophobic nature of these lipids poses a barrier for a vast majority
of peptides and proteins from crossing the membrane. Therefore, to introduce the YB-1
N-terminal proteins into the cells an appropriate mode of delivery was required.
Numerous vehicles are available for delivering proteins into cells, including the protein
transduction domains (PTDs), also known as cell penetrating peptides (CPPs), which are
capable of transporting biological cargo from the surrounding medium into the cells.
Previous literature shows that antennapedia and TAT conjugates are the most extensively
used delivery systems. For our purpose, we were looking for a peptide delivery system,
which could be used at optimal concentrations for longer time periods, with reasonably
low cytotoxicity and yet providing efficient and rapid uptake of the bound peptide to be
delivered into cells. It has been shown previously that in terms of uptake and toxicity,
antennapedia proves to be the most optimal cell penetrating peptide for peptide delivery
in vitro as compared to the other peptides (Jones et al., 2005). A 16-amino acid long
polypeptide corresponding to the third helix of antennapedia homeodomain
(RQIKIWFQNRRMKWKK) is the minimal sequence required for successful
translocation across the cell membrane (Derossi et al., 1994 and1996). Therefore to
deliver the YB-1 truncated proteins into cells we utilized the antennapedia homeodomain.
We constructed three different YB-1 fusion protein clones including i) APGFP, the
control fusion protein without any YB-1 sequence, ii) APYB77GFP, the 77 amino acid
long full length YB-1 N-terminal sequence containing clone, iii) APYB36GFP, the 36
amino acid long peptide with the internal deletion Δ12-52 (APYB36Δ12-52GFP
represented as APYB36GFP) containing clone and iv) APYB26GFP, the 26 amino acid
long proline rich YB-1 N-terminal sequence containing clone. The APYB26GFP fusion
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protein was constructed keeping in mind the importance of proline rich domains in
various cellular functions. Proline rich domains are important for signal transduction
(Vidal et al., 2001). They are needed for proper protein folding (Kusano et al., 2001) and
important for growth hormone receptor signal transduction (Goujon et al., 1994). YB-1
N-terminus has a stretch of 26 amino acids, which are extremely rich in alanines and
prolines. To test our hypothesis implicating the YB-1 N- terminus for its role in cell
proliferation, it is imperative to study the significance of just the proline rich sequence.
The YB-1 N-terminal fusion peptide sequences were expressed as fusion proteins
with sequences encoding the antennapedia for internalization and GFP for visualization
inside cells. The rat hepatoma cell system was used for testing of our hypothesis. The
objective of this study was to investigate if introduction of these N-terminal peptides,
using the antennapedia mimics the defects seen in the heterozygous mutant DT-40 cells
from the previous study and thereby test our hypothesis.
2.2

Materials and methods

2.2.1 Antibodies and reagents
All the chemical reagents, unless otherwise specified were purchased from SigmaAldrich (St. Louis, MO). The Minimum essential medium (cat # 11095-080), Dulbecco’s
modified medium (cat # 1965-092), Penicillin-Streptomycin (cat # 15140-148) and
Trypsin-EDTA (cat # 25300) was obtained from Invitrogen-Gibco (Carlsbad, CA). The
YB-1 polyclonal antibody (10mg/ml) was generated for our lab by Sigma. The antibody
against GFP (cat # A11122, 2 mg/ml) and the fluorescent-labeled secondary antibodies
(cat #s A21429 and A11029, 2mg/ml) were from Invitrogen-Molecular probes (Carlsbad,
CA). The chemiluminescence western blot developing solution kit (cat # 34080) and the
BCA protein assay kit (cat # 23225) was from Pierce (Rockford, IL). The Vectashield
Mounting Medium containing DAPI (cat # H-1200) was from Vector laboratories
(Burlingame, CA). The protein A Sepharose beads (cat # 17-0780-01) were from
Amersham Biosciences (Piscataway, NJ). The Aposcreen TM Annexin V-FITC kit (cat #
10010-02) was from Southern Biotechnology Associates Inc. (Birmingham, AL).
2.2.2 Cloning and expression of APGFP-fusion proteins
The strategy used for cloning is shown in Fig. 2.2. The three amino-terminal YB-1
sequences used for cloning are shown in Fig. 2.3. pUC966 vector modified in our lab was
used as a backbone for all sequences. The 26 amino acid alanine-proline rich YB-1
N-terminal sequence was cloned at the EcoR1 site. By varying our template and PCR
conditions the 36 amino acid long truncated version of YB-1 N-terminus with an internal
deletion of Δ12-52 and the 77 amino acid long full length YB-1 N-terminus were cloned
at the Bam H1 site of pUC966 vector. All sequences were cloned inframe with an
upstream coding sequence for the 16 amino acid long antennapedia homeodomain and
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Fig. 2.2 Strategy of cloning the APGFP fusion proteins
The APGFP fusion proteins were cloned in pUC966 vector. The YB-1 N-terminal
sequences were flanked by the antennapedia sequence on its 3′ end and the GFP sequence
on its 5′ end.

Fig. 2.3 YB-1 N-terminal amino acid sequences used for cloning
For each construct the YB-1 N-terminal amino acids and their positions in YB-1 protein
are shown. APYB77GFP contains the initial 77 amino acids from YB-1 N-terminus.
APYB26GFP sequence contained 26 amino acids proline alanine rich sequence from the
YB-1 N-terminus. APYB36GFP contains 36 amino acids from the initial 77 amino acids
of the YB-1 N-terminus with an internal deletion of amino acids in position 12 to 52.
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downstream coding sequence for GFP. E.Coli Top 10 competent cells were used for
transformation and plasmid isolation. The DNA sequences and insert orientation were
confirmed by DNA sequencing (University of Tennessee, Molecular Resource Center).
The three clones APYB26GFP, APYB36GFP and APYB77GFP and the control clone
APGFP, which lacked YB-1 sequence, were then transformed into E.Coli BL21DE3
cells. Protein expression was induced by 1mM IPTG in a culture of exponentially
growing cells. Overnight-induced cultures were harvested by centrifugation at 5000 g for
15 min. at 4°C. The pellets were stored at - 80°C or processed for purification of fusion
proteins.
2.2.3 Purification of proteins
Cell lysis and isolation of inclusion bodies were done as described previously
(Marston et al., 1984; Marston 1987). In short, each gram of pellet was resuspended in 3
ml. lysis buffer (50 mM Tris-Cl (pH 8.0), 1mM EDTA and 100 mM NaCl). 8 µl of 50
mM PMSF and 80 µl of 10 mg/ml lysozyme was added to it and left on ice for 20 min.
with occasional stirring. 4 mg of deoxycholic acid per gram of pellet was added to this
mixture while stirring continuously. It was stirred at 37°C until the lysate became
viscous. 20 µl of 1mg/ml DNAse I was added and the lysate was kept at room
temperature until it was no longer viscous (about 30-45 min.). It was then centrifuged at
12000 g for 15 min. at 4°C. The supernatant was frozen and stored at -80°C. The pellet
was resuspended in 9 volumes of lysis buffer with the same composition as mentioned
previously containing 0.5% Triton X-100 and 10mM EDTA (pH 8.0) and kept at room
temperature for 5 min.. The lysate was centrifuged as mentioned previously and the
supernatant was stored separately. Equivalent quantities of the supernatants and pellet
were analyzed on a 12% SDS-PAGE gel with coomassie blue staining. We detected most
of our proteins in inclusion bodies.
For solubilization of inclusion bodies, the pellets were resuspended in 10 volumes
solubilization buffer (8M Urea and 10mM β-Mercaptoethanol) and incubated on a
nutator for 5 hrs. at 4°C, followed by centrifugation at 11000 g. The supernatant was
frozen at -80°C and the pellet was again resuspended in the solubilization buffer for
similar processing. The fusion proteins were further purified from the supernatants using
DEAE Sephacel ion-exchange chromatography at 4°C as described previously (Crawford
et al., 2004). The expected fusion proteins were detected in fractions eluted with 0.3 M
NaCl. These fractions were dialyzed overnight at 4°C with 4 changes of buffer (50 mM
Tris-Cl (pH 8.0), 100 mM NaCl and 5% glycerol). Purity of the proteins was determined
by running triplicates of the protein fractions on a 15% SDS-PAGE gel for coomassie
staining, silver staining and western blotting using an antibody against the GFP. All the
proteins were purified to more than 70% as assessed by polyacrylamide gel
electrophoresis, followed by coomassie blue staining as shown in Fig. 2.4. The
organization of these constructs and their respective sizes on a western blot are shown in
Fig. 2.5. Western blot analysis revealed only the fusion proteins of expected sizes.
Protein concentration was checked using the BCA protein assay kit.
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Fig. 2.4 Purified fusion proteins on a SDS-PAGE gel
The APGFP fusion proteins were purified by DEAE-sephacel chromatography, dialyzed,
quantitated and equivalent amounts analyzed for purity by polyacrylamide gel
electrophoresis and coomassie blue staining. The molecular weights are shown towards
the left of the gel picture. The proteins got are about 80% pure.

Fig. 2.5 Schematic representation of the four clones and their sizes on a SDS-PAGE
Western blot
The YB-1 sequences were cloned with an upstream antennapedia and downstream GFP
sequence. APGFP clone lacks the YB-1 sequence and is used as a control fusion protein.
The organization of the four clones and their respective sizes on a western blot probed
with GFP antibody is shown. The molecular weights are mentioned on the left of the gel.

24

2.2.4 Cell culture
Rat Hepatoma cells (ATCC # H-411E) were grown in monolayers in Minimum
Essential Medium (MEM) supplemented with 10% FBS, 100U/ml Penicillin and 100
μg/ml Streptomycin, in a humidified incubator maintained at 37°C and 5% CO2 : 95% air.
Cells were fed every day and subcultured 1:5 when they became confluent, using 0.05%
trypsin-EDTA. After expansion the cells were frozen in liquid nitrogen in a medium
containing a final concentration of 80% MEM, 10% FBS and 10% DMSO. For culture,
the frozen cells vial were quickly thawed and added to the prewarmed culture medium
mentioned above. The rat aortic smooth muscle (RASM) cells were similarly cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM). For the experiments, cells were
incubated with 40 μg/ml of the purified fusion proteins for the mentioned time periods.
Where indicated the cells were incubated with 20 % FBS or U.V. irradiation (40 J/m2) in
the absence of proteins. The U.V. treatment was given in a CAMAG UV cabinet with a
UV lamp (100W) set at 366 nm at a distance of 7 cms. from the cells, at room
temperature. The total dose provided was 40 J/m2.
2.2.5 Immunoblotting
Cells were washed and lysed with RIPA buffer as described previously (Derossi et
al. 1996). Samples were sonicated at Branson 4 setting for 8 cycles of 15 sec each, stored
on ice for 30 min. and clarified by high-speed centrifugation at 8000 g. for 5 min. at 4°C.
The supernatant was used as the whole cell extracts. For nuclear and cytoplasmic
fractions, the cells were scraped in 100 μl ice cold PBS and centrifuged at 500 g for 5
min. The cell pellet was resuspended in 100 μl Buffer A (50 mM NaCl, 10 mM HEPES
pH-8.0, 500 mM sucrose, 1mM EDTA, 0.2% Triton-X-100, freshly added protease
inhibitors – 1 μg/ml leupeptin, 1 μg/ml aprotinin and 1 mM PMSF and 7mM βMercaptoethanol), vortexed at high speed for 45 sec., spun down at 2000 g for 2 min. at
4°C and the supernatant was used as cytoplasmic extract. The pellet was resuspended in
100 μl Buffer B (Buffer A with 25% glycerol and 0.1 mM EDTA) and spun down at
2000 g for 2min. at 4°C. The resulting pellet was resuspended in 50 μl Buffer C (Buffer
B with 350 mM NaCl), incubated on ice for 30 min. with intermittent high speed
vortexing and spun down at 11000 g for 15 min at 4°C. The resulting supernatant was
diluted to 100 μl with ice cold PBS was used as nuclear extract. Equivalent amounts of
samples were used for immunoblotting on a 15% SDS-PAGE gel. Rabbit antibody
against GFP was used as primary antibody at 1:7500 dilution for overnight incubation at
4°C and HRP conjugated Anti-Rabbit IgG was used as secondary antibody at 1:15000
dilution for 2 hrs. at room temperature. The blots were developed using
chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate) according to
the manufacture’s protocol.
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2.2.6 Immunocytochemistry and indirect immunofluorescence
Cells were rinsed twice with phosphate buffered saline (PBS), fixed for 15 min.
with 4% p-formaldehyde, washed twice with PBS and stored at 4°C, until all time point
samples had been collected. Cells were blocked with 5% goat serum and 3% BSA in PBS
for 30 min. and rinsed with PBS thrice. Then the cells were incubated with primary
antibodies rabbit anti-GFP (1:500) or mouse-anti-YB-1 (1:300) and rabbit anti-cyclin D1
(1:300) for 3 hrs. followed by several washes with PBS. Subsequently cells were
incubated with secondary antibodies FITC conjugated Anti-Rabbit IgG (1:500) and
Texas-Red conjugated Anti-Mouse IgG (1:500) for 1 hr. at room temperature in the
absence of light. Coverslips were washed several times with PBS and once with water to
remove any salts and then left to air-dry for 45 min. in the absence of light. The
coverslips were mounted onto glass slides using Vectashield Mounting Medium
containing DAPI to counter stain nuclei. The slides were stored at -20°C until analyzed
by microscopy.
2.2.7 Microscopy
Confocal images were captured using LSM 510 confocal laser-scanning three-color
microscope (Carl Zeiss, Jena, Germany). Images were captured using Argon laser at 75%
output and HeNe1 laser at excitation wavelengths 488 nm and 543 nm respectively.
Optical slice thickness was set at 0.3 μm, magnification to 40x and sections presented
were taken approximately at the mid height level of cells. Photomultiplier gain and laser
power were identical within each experiment. Apoptotic blebs were seen using Axioplan
2 epifluorescent microscope (Zeiss, Germany). DAPI fluorescence was captured using
the 63X magnification lens of the microscope. Axiovision software was used to capture
zvi-stacks of images. Exposure was set using control nuclei and was fixed for each
experiment. A minimum of 100 stained cells were scored for each experiment reported.
All images were analyzed and adjusted for contrast in Adobe Photoshop 5.0 (San Jose,
CA).
2.2.8 DNA fragmentation
Exponentially growing cells were incubated with the fusion proteins as mentioned
previously for 24, 48 and 72 hrs. Analysis of DNA fragmentation was done on these cells
as described previously (Swamynathan et al., 2002). In short, treated cells were
harvested, suspended in TNE buffer (1M NaCl, 20mM Tris-HCl, pH 7.4, 2mM EDTA
and 0.6% SDS) and incubated overnight on ice. The next day, the cellular debris was
spun down at 12000 g at 4°C for 45 min. The supernatant was treated with RNAseA (100
μg/ml) for 30 min at 37°C. The DNA was phenol chloroform purified and precipitated
with ethanol. The DNA pellet was resuspended in TE buffer (Tris-HCl 10mM and EDTA
1mM) and an aliquot was used to analyze it on an agarose gel with ethidium bromide
staining and photographed under UV illumination (Fotodyne Inc., Hartland, WI).
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2.2.9 FACS analysis
For confirmation of successful synchronization and cell cycle analysis,
synchronized cells were harvested by trypsinization or scraping on ice and pelleted down
at 500 g for 5 min. The pellet was washed with PBS, cells were fixed with ice cold 70%
ethanol, incubated on ice for 45 min. and pelleted down at 500 g for 5 min. The pellet
was washed with hanks balanced salt solution (HBSS) containing 1% BSA. The resulting
pellet was resuspended in Propidium Iodide buffer (1:1 dilution of 20ug/ml of PI in
HBSS and 1 mg/ml RNAse A) and incubated for 30 min. in a 37°C water bath. Samples
were analyzed using a Becton Dickinson FACS Calibur. The cell cycle analysis software
was used to determine the % of cells in each phase of cell cycle. For analysis of apoptotic
cells, Aposcreen TM Annexin V-FITC kit was used according to the manufacturer’s
protocol. Cell debris was excluded from the FACS analysis by doing appropriate forward
and light scatter gating. Differences in GFP and FITC staining were adjusted by using
GFP negative and annexin V FITC positive controls for non specific signals and triplicate
experiments with and without annexin V FITC samples and appropriate gating for the
experimental samples. Profiles were analyzed and bar graphs were plotted using
Microsoft Excel.
2.2.10 Quantitation of immunoblotting and immunofluorescence data
All immunoblot images were scanned and exported as TIFF files to Adobe
Photoshop software (San Hose, CA) for subsequent analysis. Each image was adjusted to
invert the scale. A box was drawn around the biggest band using Marquee tool and
histogram analysis was done. The mean was noted down and then the same box was used
to drag down to another band to repeat the process. For each band, representative
integrated density values were computed after subtracting the background density. For
the immunofluorescence data, each stack of confocal images were imported and opened
on the LSM image scanner. The histogram analysis was performed on atleast 4 cells from
each slice and atleast 4 slices for each experiment and all the slices were analyzed for the
same cells. To start with, the outlining tool was used to demarcate the total cell area. The
total pixel count was noted down for the whole cell. Then the cell nucleus was
demarcated and the nuclear pixel count was noted down. This was done on atleast 4
sections from each cell. The total cell pixels and the total nuclear pixels were added up
from all sections and the % of the nuclear pixels was calculated. This gave the % of
nuclear protein as compared to the total cell protein.
2.2.11 Data analysis
For all the FACS analysis experiments, values from three independent experiments
were used to draw the graphs on Microsoft Excel. Statistical significance was tested by
performing unpaired student’s t-tests using the GraphPad Software. Results were
considered statistically significant if the P value of <0.001 was reached. However the P
value of each experiment is mentioned separately in the results section.
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2.3 Results
2.3.1 APYBGFP and APGFP fusion proteins get internalized and are stable inside the
cells
Earlier studies from our laboratory indicated that the amino end of YB-1 might
exert a role in cell proliferation (Swamynathan et al., 2002, Figs 1.3 and 1.4). Therefore,
we expressed a fusion protein containing the 77 amino acids, APYB77GFP in E.coli.
Two other fusion proteins containing 36 amino acids with an internal deletion,
APYB36GFP and the alanine-proline rich 26 amino acid sequences from YB-1 amino
end, APYB26GFP were also expressed. All the constructs contained the fusion
facilitating 16 amino acid antennapedia peptide (RQIKIWFQNRRMKWKK) at the
amino end and the reporter gene, encoding GFP at the carboxy end of the YB-1 sequence.
Three mechanisms have been proposed to explain how Antennapedia bound peptides get
transduced across membranes. They are i) inverse micelles are formed and the cargo is
captured in an aqueous compartment to move across the membrane (Derossi et al., 1996;
Prochiantz, 1996; Binder et al., 2003), ii) the peptide crosses biological membranes in an
electroporation like mechanism (Richard et al., 2003) and iii) the peptide relies on the
endocytic pathways for it to be delivered into the cells (Richard et al., 2003).
To confirm that our fusion proteins get translocated into and are stable inside the
cells for significant time periods, we incubated rat hepatoma cells with 40 μg/ml of each
protein for 3 hrs. and 18 hrs. Western blotting analysis of the whole cell extracts
confirmed that the fusion proteins get internalized as early as 3 hrs. (Fig. 2.6, top panel)
and are stable at the 18 hr. time point of incubation (Fig. 2.6, bottom panel). Similar
results were obtained with primary cells isolated from rat aortic smooth muscle (data not
shown). We conclude that the peptides are internalized in different cell types and that
they are not degraded during incubation.
2.3.2 YB-1 sequence appears to restrict to cell cytoplasm
Having demonstrated internalization of all the proteins, we then investigated the
localization of these proteins within cells by immunocytochemistry and indirect
immunofluorescence. Cells grown on coverslips were incubated with 40 μg/ml of the
fusion proteins for 3 hrs. and 18 hrs., for analysis by confocal microscopy. The cells were
fixed and anti-GFP was used as primary antibody followed by FITC conjugated antirabbit IgG as the secondary antibody. By visual inspection of the confocal images we
found that approximately 70% of the cells had taken up the protein by 18 hrs. The results
indicate that the APGFP is internalized and distributed throughout the cell, localizing in
both nucleus and cytoplasm (Fig. 2.7, panels A and E). In contrast, all the three YB-1
fusion proteins are seen localized only in the cytoplasm (Fig. 2.7, panels B to D and F to
H). We found that the levels of internalized fusion proteins seen in the cells at 18 hrs. are
significantly higher than those seen at the 3 hr. time point. Similar results were obtained
with primary cultures of rat aortic smooth muscle cells (RASM cells), indicating that it is
not unique to rat hepatoma cells (data not shown).
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Fig. 2.6 APYBGFP and APGFP fusion proteins get internalized and are stable
inside the cells
Rat hepatoma cells at ~70% confluency were incubated with 40 μg/ml of each fusion
protein for 3 and 18 hrs. Immunoblot analysis of whole cell extracts with polyclonal
antibody against GFP shows the uninternalized peptides in the incubation mixture (I), the
non-specifically bound peptides in the PBS wash (P) and the internalized peptides in the
lysed fractions (L). Note that all four fusion proteins show internalization and stability at
the 3hrs. and 18hrs. time points.
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Fig. 2.7 APYBGFP fusion proteins are localized in cell cytoplasm
Rat hepatoma cells grown on cover slips to ~70% confluency were incubated with 40
μg/ml of each fusion protein for 3 and 18 hrs. for immunocytochemistry and indirect
immunofluorescence analysis of sub-cellular distribution of the proteins. Cells were fixed
with 4% p-formaldehyde, blocked with 3% goat serum and BSA and probed for the
fusion proteins with antibody against GFP and FITC labeled secondary antibody. The
sub-cellular distribution of the proteins analyzed by confocal microscopy is indicated by
the arrows. Cells not incubated with the proteins acted as a negative control and these
slides were used for optimization to minimize the non-specific binding and background
fluorescence. The APYB26GFP (panels B and F), APYB36GFP (panels C and G), and
APYB77GFP (panels D and H) proteins were seen exclusively in the cytoplasm, whereas
APGFP was seen in both nucleus and cytoplasm (panels A and E).

30

In order to confirm this result, we performed western blotting analysis on the
nuclear and cytoplasm extracts of incubated rat hepatoma cells. We detected GFP signal
only in the cytoplasmic extracts of cells incubated with the APYBGFP proteins even after
18 hrs. whereas the signals were seen in both nuclear and cytoplasmic extracts of APGFP
incubated cells (Fig. 2.8). We conclude that the presence of YB-1 sequences in the fusion
proteins is responsible for their restricted localization to cytoplasm of cells and that the
initial proline rich 26 amino acids of YB-1 N-terminal sequence is sufficient for this
differential localization.
2.3.3 Effect of external stimuli on the localization of APYBGFP proteins
Previous studies showed that cells exposed to extracellular stimuli like U.V.
irradiation (Koike et al., 1997), anticancer drugs (Kohno et al., 2003), hyperthermia
(Stein et al., 2001) or viral infection (Kohno et al., 2003) resulted in the translocation of
YB-1 from the cell cytoplasm to nucleus. In order to investigate if the above-mentioned
stimuli resulted in nuclear translocation of the YB-1 fusion proteins, rat hepatoma cells
incubated with the fusion peptides were stimulated with either 20% FBS or U.V.
irradiation (40 J/m2) in protein free medium for 3 and 18 hrs. respectively. For 20% FBS
stimulation, after fusion protein incubation in normal medium, the cells were incubated
with protein free medium containing 20% FBS for different time periods. For UV
stimulation, after the fusion protein incubations, the cells were treated with a total of
40 J/m2 of UV irradiation in a CAMAG chamber and then placed in the incubator in
normal protein free medium for the two time periods. Nuclear and cytoplasmic extracts of
these cells were used for western blotting with GFP antibody. Serum stimulation resulted
in about 25 to 28 % of nuclear translocation of all three APYBGFP proteins after 3 hrs
and about 30 to 35 % after 18 hrs. (Fig. 2.9, panels 1 and 2). U.V. irradiation stimuli
resulted in nuclear translocation of about 35 % APYB77GFP protein in 3 hrs and about
38% in 18 hrs. (Fig. 2.9, panels 3 and 4), whereas APYB26GFP and APYB36GFP were
seen only in the cytoplasmic extracts at both time points (Fig. 2.9, panels 3 and 4). These
results suggest that full length YB-1 N-terminus is required for the translocation of YB-1
from cytoplasm to nucleus under U.V. stimulation. APGFP was detected in both nuclear
and cytoplasmic extracts under both stimuli.
In order to further confirm these results, we performed immunocytochemistry on
cells grown on cover slips and incubated similarly. We detected the presence of about 3237% nuclear translocation all three APYBGFP proteins in 3hrs and about 38-39% after
18 hrs. under serum stimuli (Fig. 2.10, panels B to D and F to H), thereby confirming our
immunoblotting results. In case of U.V. stimulated cells, we detected about 32% nuclear
APYB77GFP in 3 hrs and about 39 % in 18 hrs. (Fig. 2.11, panels D and H), whereas,
APYB26GFP and APYB36GFP were seen only in nucleus (Fig. 2.11, panels B, C, F and
G). APGFP in both instances was seen both in nucleus and cytoplasm.
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Fig. 2.8 Cytoplasmic localization of the APYBGFP fusion proteins confirmed by
western blotting
Rat hepatoma cells at ~70% confluency were incubated with 40 μg/ml of each fusion
protein for 3 and 18 hrs. Their nuclear (N) and cytoplasmic (C) extracts were analyzed
for the fusion protein distribution by immunoblotting using polyclonal GFP antibody.
Note that the three APYBGFP proteins were detected only in cytoplasmic extracts of
cells at both time points. In contrast, APGFP was detected in both nuclear and
cytoplasmic extracts. This confirms the results got from the immunocytochemistry
experiment shown in Fig 2.7.
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Fig. 2.9 Localization of the APYBGFP proteins in rat hepatoma cells changes in
response to different stimuli
To investigate the sub-cellular localization of the fusion proteins after serum or UV
stimulation, rat hepatoma cells at ~70% confluency were incubated with 40 μg/ml of each
fusion protein for 3hrs. and then stimulated with 20% FBS or 40 J/m2 U.V. irradiation.
Serum stimulation was provided by incubating cells in a protein free medium containing
20% FBS for 3 and 18 hrs. UV stimulation was provided by incubating the cells in
protein free medium in a CAMAG UV chamber for total irradiation of 40 J/m2 followed
by incubation in the incubator for 3 and 18 hrs. Their nuclear (N) and cytoplasmic (C)
extracts were analyzed by immunoblotting with GFP antibody. Note that under serum
stimuli (top two panels), about 25-28% nuclear translocation of all APYBGFP fusion
proteins was seen after 3 hrs incubation and about 30-35% after 18 hrs. UV stimuli
(botton two panels) resulted in about 35% nuclear translocation of only APYB77GFP
after 3 hrs. and about 38 % after 18 hrs.. APGFP was detected in both nuclear (N) and
cytoplasmic extracts (C) irrespective of the stimuli provided.
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Fig. 2.10 APYBGFP fusion proteins partially translocated to the nucleus following
20% FBS treatment
Rat hepatoma cells grown on cover slips to ~70% confluency were incubated with 40
μg/ml of each fusion protein for 3 hrs. and then stimulate with serum by incubation in a
protein free medium containing 20% FBS for 3 and 18 hrs. for immunocytochemistry and
indirect immunofluorescence analysis of sub-cellular distribution of the proteins under
serum stimuli. Cells were fixed with 4% p-formaldehyde, blocked with 3% goat serum
and BSA and probed for the fusion proteins with antibody against GFP and FITC labeled
secondary antibody. The sub-cellular distribution of the proteins analyzed by confocal
microscopy is indicated by the arrows. Cells not incubated with the proteins acted as a
negative control and these slides were used for optimization to minimize the non-specific
binding and background fluorescence. About 32-37% nuclear translocation of all three
APYBGFP fusion proteins was seen after 3 hrs (panels B, C and D) and about 38-39%
after 18 hrs. (panels F, G and H). The localization of APGFP did not change in
comparison to the unstimulated cells (panels A and E). This confirms the western blotting
result seen in Fig. 2.9.
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Fig. 2.11 APYB77GFP gets partially translocated to the nucleus under UV
treatment
Rat hepatoma cells grown on cover slips to ~70% confluency were incubated with 40
μg/ml of each fusion protein for 3 hrs. and then stimulate with 40 J/m2 U.V. irradiation in
a CAMAG UV chamber followed by incubation in a protein free medium containing for
3 and 18 hrs. for immunocytochemistry and indirect immunofluorescence analysis of subcellular distribution of the proteins under UV stimuli. Cells were fixed with 4% pformaldehyde, blocked with 3% goat serum and BSA and probed for the fusion proteins
with antibody against GFP and FITC labeled secondary antibody. The sub-cellular
distribution of the proteins analyzed by confocal microscopy is indicated by the arrows.
Cells not incubated with the proteins acted as a negative control and these slides were
used for optimization to minimize the non-specific binding and background fluorescence.
About 32 % APYB77GFP was seen translocated to the nucleus after 3 hrs (panel D) and
about 39% after 18 hrs (panel H), whereas APYB26GFP and APYB36GFP were seen
localized only in the cytoplasm (panels B and F and C and G). Localization of APGFP is
comparable to that of the unstimulated cells (panels A and E). This confirms the western
blotting result seen in Fig. 2.9.
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2.3.4 Effect of APYBGFP proteins on cell cycle
Cell cycle progression is mainly controlled by several key checkpoints, including
G1/S checkpoint, S-phase DNA damage checkpoint and G2/M spindle integrity
checkpoint. Previously reported defects in heterozygous mutant DT40 cells resembled the
ones typical of cells with a defect at G2/M phase of cell cycle (Swamynathan et al.,
2002). In order to study the effects of internalization of the proteins into rat hepatoma
cells, we had to ensure that the fusion proteins are stable inside the cells for prolonged
time periods. Therefore a preliminary experiment was performed, in which cells were
incubated with the fusion proteins as described previously, for 24, 48 and 72 hrs. Whole
cell lysates of the incubated cells were prepared and analyzed to investigate the stability
of the internalized proteins. The principle here is that the stable proteins should produce a
single band on the exposed film, whereas unstable proteins should show more than one
bands, formed by degradation of the protein. We detected single bands, indicated by the
GFP signals seen at full length sizes of all four proteins (Fig. 2.12). Among the three
replicate experiments done to confirm the stability, only one showed a slight degradation
of APYB77GFP. However the degraded product was quantitatively very low in
comparison to the full length protein. The other two replicates did not show any
degradation. Therefore we conclude that the proteins are stable atleast till the 72 hrs. time
point of incubation.
In order to investigate if the cell cycle abnormalities are due to the N-terminal
YB-1 proteins, rat hepatoma cells were incubated with 40 μg/ml of each of the
APYBGFP and APGFP proteins, respectively, for 24, 48 and 72 hrs. Half of each of the
harvested samples was processed for propidium iodide staining and cell cycle analysis as
described in methods. At any given time point in cell cycle in actively proliferating cells,
a very high proportion of the cells are in the G1 phase and lesser than 10% in the G2
phase. FACS analysis of the cells incubated with the APYB77GFP protein indicated that
about 32% of cells were in G2/M phase of cell cycle by 72 hrs (Fig. 2.13). More than
24% of cells were in G2/M phase when treated with APYB26GFP (Fig. 2.13). In
contrast, the APYB36GFP incubated cells showed only 8% to 12% cells in the G2/M
phase of cell cycle (Fig. 2.13). Control treatment with APGFP showed only 4-7% of cells
in the G2/M phase, which is comparable to the proportion of G2/M phase cells in
unincubated samples (Fig. 2.13). All reported differences are significant to P< 0.0005.
We conclude that the APYBGFP incubation resulted in a significant cell cycle arrest at
the G2/M phase.
The remaining half of the samples were used to quantitate the GFP positive cells
(Table 2.1) and the mean GFP fluorescence of each sample (Table 2.2). Results indicate
that in all treatments comparable percentage of cells show fusion protein internalization.
The mean GFP fluorescence seen in the four samples at each time point was also similar.
This suggests that the differences in proportions of G2/M phase cells was not due to
variation in the number of fusion protein-positive cells or amount of the internalized
fusion proteins, but due to the presence of YB-1 N-terminal sequences in the three
APYBGFP clones. These results render support for our hypothesis that the introduction
of YB-1 N-terminal proteins into cells causes a defect in the G2/M phase of cell cycle.
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Fig. 2.12 APYBGFP fusion proteins are stable until the 72 hrs. time point of
incubation
In order to investigate the stability of the proteins uopto 72 hrs of incubation, rat
hepatoma cells at ~70% confluency were incubated with 40 μg/ml of each fusion protein
for 24, 48 and 72 hrs. A representative blot from the immunoblotting analysis of whole
cell extracts with polyclonal antibody against GFP shows that all proteins are intact even
after 72 hrs. of incubation.
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Fig. 2.13 Cells incubated with the APYBGFP proteins show cell cycle arrest at the
G2/M phase of cell cycle
Exponentially growing rat hepatoma cells incubated with 40 μg/ml of the APYBGFP and
APGFP proteins for 24, 48 and 72 hrs. were harvested and stained with propidium iodide.
FACS analysis indicated that APYB77GFP incubation resulted in about 12-32 % cells in
the G2/M phase of cell cycle and APYB26GFP incubation led to 8-23% G2/M phase
cells. This was significantly higher than unincubated cells (data not shown) or APGFP
incubated cells at all three time points. Only 8-12% G2/M phase cells were detected in
case of APYB36GFP incubation. All reported differences are significant to P< 0.0005.
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Table 2.1 GFP positive cell % in cell cycle assay as determined by FACS analysis

Time

APGFP

APYB26GFP APYB36GFP APYB77GFP

24 hrs.

67

69.6

69.9

70.9

48 hrs.

77.8

82.1

77.8

79.6

72 hrs.

85.8

86.4

84.5

86.5

This table shows the % of GFP positive cells from a representative experiment. We
detected comparable % of GFP positive cells in all four types of fusion protein incubated
samples at a given time point.

Table 2.2 Mean GFP fluorescence in cell cycle assay as determined by FACS
analysis

Time

APGFP

APYB26GFP APYB36GFP APYB77GFP

24 hrs.

3753

3027

3417

3848

48 hrs.

4125

4347

4155

4242

72 hrs.

4952

6327

6018

4895

This representative table shows that all the samples used in the experiment for cell cycle
analysis have nearly the same amounts of protein uptake at any given time point,
measured in terms of the mean fluorescence.
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2.3.5 YB-1 amino terminal domain is involved in significant apoptosis
Reduction in levels of YB-1 results in significant cell death. A recent study
demonstrated that when YB-1 levels are downregulated, an increased rate of apoptotic
cell death was observed (Shibahara et al., 2004), thereby showing a direct relation
between YB-1 levels and apoptosis. Lately it was shown that siRNA mediated
knockdown of YB-1, led to growth arrest and induction of apoptosis in multiple myeloma
cells (Chatterjee et al., 2007). Previous studies from our laboratory (Swamynathan et al.,
2002) also showed apoptosis in heterozygous mutant DT40 cells and that this might be
due to a dominant negative effect of a potential truncated protein formed. Therefore we
decided to study if apoptosis can be seen in cells with internalized APYBGFP proteins.
One of the hallmarks of apoptotic cells is the display of phosphotidylserine on their
cell surfaces, which can be detected by using a fluorescent dye conjugated Annexin V.
We incubated cells with 40 μg/ml of each the four fusion proteins respectively for 24, 48
and 72 hrs. and harvested the cells. Half of each of these samples were processed for
Annexin V staining as described previously in methods and analyzed by FACS analysis.
Three independent experiments were performed for this analysis. As seen from Fig. 2.14,
APGFP incubated cells show negligible apoptosis at all three time points. In contrast, a
high proportion of apoptotic cells were detected in APYB77GFP incubated cells. As
early as 24 hrs of incubation, about 8-9% of the cells were apoptotic, increasing to 1718% at the 48 hrs. time points and an average of about 22-23 % by the 72 hrs. time
points. APYB36GFP incubated cells also show apoptosis reaching to about 11-12% by
the 72 hrs. time point, which though was higher than the control, was still statistically
very low as compared to the APYB77GFP incubation. Most interestingly, APYB26GFP
incubated cells show approximately 6-7% of apoptosis at 24 hrs., about 9-10% by the 48
hrs. and the proportion increased to about 18-19% by 72 hrs (Fig. 2.14). All differences
reported are significant to P< 0.0007.
In order to confirm that the apoptosis seen in the above experiment was not due to
differences in the number of GFP positive cells or the quantitative uptake of the proteins,
we quantitated the proportion of GFP positive cells and the mean GFP fluorescence.
Results indicate that the % of GFP positive cells and the mean GFP fluorescence is
approximately the same in all four proteins’ incubation over the three time points (Table
2.3 and 2.4).
Another hallmark of apoptosis is karyorrhexis, during which the nuclear envelope
becomes discontinuous and the DNA gets fragmented giving a characteristic ladder like
appearance. Cells were incubated with proteins for the three time periods, DNA was
isolated and analyzed on a 1.2% agarose gel. DNA fragmentation pattern in the form of a
180-200 bps ladder was clearly observed in the lanes with DNA from the APYBGFP
proteins incubated cells, whereas cells incubated with the control protein, APGFP,
showed intact full length DNA (Fig. 2.15). We observed that there is an increasing level
of the laddered pattern seen in all the 3 protein incubated cells for time points 24 to 72
hrs., signifying an increase in the proportion of apoptotic cells (Fig. 2.15). However DNA
laddering in the APYB36GFP incubated cells was less as compared to the APYB26GFP
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Fig. 2.14 APYBGFP protein incubation results in significant apoptosis by Annexin
V staining and FACS analysis
Exponentially growing rat hepatoma cells incubated with 40 μg/ml of the APYBGFP and
APGFP proteins for 24, 48 and 72 hrs. were harvested and stained with FITC conjugated
Annexin V. FACS analysis indicated that APYB77GFP incubation resulted in about 8 to
23% apoptotic cells and APYB26GFP incubation led to 7 to 19% apoptotic cells. Only 5
to 10% apoptotic cells were detected in case of APYB36GFP incubation. The apoptosis
in APGFP incubated cells was statistically insignificant. All reported differences are
significant to P< 0.0007.
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Table 2.3 GFP positive cell % in apoptotic assay as determined by FACS analysis

Time

APGFP

APYB26GFP APYB36GFP APYB77GFP

24 hrs.

77.3

77.1

77.0

77.7

48 hrs.

79.8

77.8

79.7

79.8

72 hrs.

81.3

82.9

83.6

84.0

The % of GFP positive cells is listed out from one representative experiment. We
detected comparable % of GFP positive cells in all four types of fusion protein incubated
samples at a given time point.

Table 2.4 Mean GFP fluorescence in apoptotic assay as determined by FACS
analysis

Time

APGFP

APYB26GFP APYB36GFP APYB77GFP

24 hrs.

4346

5376

4923

4856

48 hrs.

5644

5554

5430

5546

72 hrs.

5962

6349

6556

5675

A representative table of the mean fluorescence of all the samples analyzed for apoptosis,
shows equivalent mean fluorescence among all samples at a given time point.
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Fig. 2.15 APYBGFP protein incubation results in significant DNA fragmentation
(Karyorrhexis)
Cellular DNA was isolated from cells incubated with the three APYBGFP or APGFP
proteins respectively for 24, 48 and 72 hrs. time points. Equivalent amounts of DNA
from these samples were loaded onto a 1.2% agarose gel. DNA ladder as expected of
apoptotic cells was detected in DNA from cells incubated with the three APYBGFP
proteins but not from the APGFP incubated cells.
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and APYB77GFP incubated cells, confirming our observations in the previous
experiment by Annexin V staining.
A third hallmark of apoptotic cells is pyknosis, during which the chromatin
undergoes condensation into compact patches against the nuclear envelope and the
nucleus breaks into several discrete chromatin bodies or nucleosomal units due to the
degradation of DNA. We analyzed the nuclei of APYBGFP incubated cells by DAPI
staining to investigate if they showed any pyknosis. We detected chromatin condensation
and the broken down nucleus in cells treated with all the 3 APYBGFP proteins for 24 to
72 hrs. (Fig. 2.16, panels B to D, F to H and J to L) whereas the nuclei of cells incubated
with the control protein APGFP showed normal appearance (Fig. 2.16, panel A, E and I).
Based on these observations we conclude that the YB-1 sequence in the three APYBGFP
clones is responsible for the cells to undergo apoptosis.
2.4 Discussion
YB-1 expression is closely associated with cell proliferation. Previous studies from
our laboratory showed that disruption of one allele of Chk-YB-1b gene in DT-40 cells
resulted in abnormal phenotypes, including slower growth rate of cells, increased
genomic DNA content that is associated with apoptosis and some morphological changes
(Swamynathan et al., 2002). We hypothesized that the abnormalities seen may be due to
the dominant negative effect exerted by a putative truncated protein product of the
disrupted allele, which spans the YB-1 N-terminus. In this study we sought to test this
hypothesis by investigating the effects of introduction of the N-terminal YB-1 sequences
as exogenous proteins into rat hepatoma cells. The fusion proteins constructed to test our
hypothesis were i) APYB77GFP, with the 77 amino acid N-terminal YB-1 sequence, till
the Sty I site, ii) APYB36GFP with the internal deletion from 12-52, iii) APYB26GFP,
with the proline rich 26 amino acid stretch and iv) APGFP, which was our control fusion
protein.
We demonstrated that internalization of the four APGFP fusion proteins occurs at
high efficiency in exponentially growing rat hepatoma cells with more than 70% cells
showing the protein within 18 hrs. of incubation. Moreover as seen from the data, the
proteins retained their stability even up to 72 hrs. of internalization. In contrast to the
control fusion protein APGFP, which is seen in both cytoplasm and nucleus, the three
APYBGFP fusion proteins showed localization restricted to the cytoplasm of cells. This
result was in agreement with previous studies showing that the YB-1 carboxy-terminal
domain harbors its nuclear localization signal and the cold shock domain contributes to
its nuclear retention (Bader et al., 2005). Yet another study showed that the YB-1
carboxy-terminal domain binds to a yet unknown anchoring protein in the cytoplasm and
thus retains the YB-1 there (Koike et al., 1997). However, the nucleocytoplasmic
shuttling of YB-1 has not been clearly understood and our results add to the current
knowledge in this field, by demonstrating that the YB-1 carboxy-terminus is not essential
for its cytoplasmic retention.
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Fig. 2.16 APYBGFP protein incubation results in significant pyknosis
Exponentially growing rat hepatoma cells incubated with 40 μg/ml of the APYBGFP and
APGFP proteins for 24, 48 and 72 hrs. were stained with DAPI. Fluorescence microscopy
was used to analyze the stained nuclei of cells The arrows in panels B to D, F to H and J
to L indicate the chromatin condensation and apoptotic nuclear bleb like formations in
the nuclei of cells incubated with APYB26GFP, APYB36GFP and APYB77GFP
proteins, whereas APGFP incubated cell nuclei (panels A, E and I) show normal
appearance.
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Though YB-1 is predominantly a cytoplasmic protein, it has been reported that
various genotoxic stresses like U.V. irradiation, hyperthermia, anticancer drugs, IF-γ
treatment and adenoviral infection result in its partial translocation to the nucleus
(Higashi et al., 2003; Kohno et al., 2003; Raffetseder et al., 2003; Zhang et al., 2003).
Here we showed that rat hepatoma cells stimulated with 20% FBS show partial nuclear
translocation of the three APYBGFP proteins from cytoplasm. 20% FBS was shown to
stimulate YB-1 phosphorylation (Evdokimova et al., 2006), which reversed mRNA
silencing by YB-1. It is likely that the mRNA free YB-1 gets translocated to the nucleus
and therefore we detected the nuclear translocation of fusion proteins.
In contrast to the serum treatment, U.V. irradiation did not stimulate nuclear
translocation of APYB26GFP and APYB36GFP. Only the APYB77GFP showed partial
translocation from the cytoplasm to nucleus. Different genotoxic stresses activate
different cellular responses to overcome stress. One previous study showed that nuclear
translocation of YB-1 under UV stimuli is mediated by protein kinase C modulated
mechanism (Koike et al., 1997). However the protein kinase C phosphorylation site on
YB-1 is in its cold shock domain at amino acid position196, which is not present in the
APYB77GFP protein. It has only one phosphorylation site at position 74 that is
phosphorylated by a casein kinase II. So if this nuclear translocation is modulated by
phosphorylation, it has to be at the position 74 and not 196. But it does not seem likely
that this might be the mechanism of nuclear translocation in this instance, since the
APYB36GFP has the amino acid 74 and yet it does not get translocated to the nucleus
under UV stimuli. But the internally deleted amino acids from the APYB36GFP protein
might have some effect on this process. The same UV stimulation experiment performed
with the APYB77GFP protein with an mutation at the 74 amino acid can give a better
idea is this nuclear translocation is mediated by phosphorylation at the position 74 amino
acid by casein kinase II.
It has also been shown that only under UV irradiation, YB-1 forms a complex with
p53/WRN, during the process of which it gets translocated into the nucleus (Guay et al.,
2006). YB-1 N-terminus is implicated in its interaction with p53 (Okamoto et al., 2000).
This is another likely mechanism, which might explain the nuclear translocation of only
APYB77GFP under UV stimuli, but not APYB26GFP and APYB36GFP, which lack the
full length N-terminus and therefore might not be able to form a complex with p53/WRN.
UV irradiation also leads to YB-1 binding to its Y-box (Uchiumi et al., 1993; Asakuno et
al., 1994). It is likely that this interaction is mediated only by the full length YB-1
N-terminus. However YB-1 cold shock domain and C-terminal domains are also shown
to be involved in binding with p53. So the mechanism of nuclear translocation of only
APYB77GFP cannot be totally explained by its ability to bind to p53 and the inability of
APYB26GFP and APYB36GFP for the same due to the lack of some residues. Analysis
of nuclear translocation of YB-1 with truncated N-terminal proteins but possessing the
CSD and CT domains can provide a better insight about the importance of the amino
terminal residues for nuclear translocation under UV stimuli.
Incubation of cells with the APYB77GFP and APYB26GFP fusion proteins also
resulted in significant cell cycle arrest at the G2/M phase. YB-1 has already been
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implicated in the prevention of premature cellular senescence (Lu et al., 2005). It is
possible that due to the dominant negative effect exerted by the N-terminal proteins, the
cells lose their ability to divide. Our results and interpretations are concurrent with the
previous knowledge available about YB-1. It is very likely that YB-1 can provoke cell
division failure by its specific interaction with actin (Ruzanov et al., 1999), because actin
filaments form contractile rings, which help cleave cells during cytokinesis (Robinson et
al., 2004). YB-1 might also directly affect centrosome functions as it binds to the
centrosome during mitosis (Janz et al., 2000). Centrosome controls cell exit from
cytokinesis (Piel et al., 2001) and cytokinesis failure leads to chromosomal instability and
aneuploidy (Lingle et al., 2002; Nigg, 2002), which might lead to a block in cell cycle
and apoptosis.
Several reports have shown the relationship between the levels of YB-1 and
induction of apoptosis (Schittek et al., 2007; Chatterjee et al., 2007). Our previous study
showed that targeted disruption of one allele of YB-1 resulted in a small proportion of
cells exhibiting apoptosis. In this study we show that the APYB77GFP and APYB26GFP
incubated cells show significant apoptosis. This result supports our hypothesis that the
defects seen in the heterozygous mutants in our previous study were the result of a
dominant negative effect of the potential truncated protein.
We performed some preliminary experiments to investigate if the G2/M phase
arrested cells from the APYB77GFP or APYB26GFP incubations are the very population
of cells that underwent apoptosis. For this purpose, we sorted out G2/M phase cells and
then analyzed the proportion of Annexin V stained cells in this population. But due to the
technical limitations of using propidium iodide and Annexin V in the same samples, the
data obtained was not very conclusive (data not shown).
In contrast to the APYB77GFP and APYB26GFP incubated cells, the
APYB36GFP incubated cells showed a lower percentage of cells blocked in the G2/M
phase of cell cycle. Incubation with APYB36GFP also resulted in apoptotic cells, albeit
much lesser in proportion to the percentage seen in case of the other two APYBGFP
fusion proteins. APYB77GFP contains all the 77 amino acids of from the YB-1
N-terminus. This includes the alanine - proline rich sequence SEAETQQPPAAPPAAPALSAADTKP, which is also present in the APYB26GFP. But
only a part of it (SSEAEQQPP) is present in APYB36GFP. Since both APYB77GFP and
APYB26GFP showed maximum effect on the cell cycle and apoptotic ability as
compared to APYB36GFP, it is very likely that this defect in cell cycle and apoptotic
ability of cells is directly or indirectly mediated by the presence of the proline rich
PPAAPPAAPALSAADTK sequence.
There is a possibility that the YB-1 proline-alanine rich residues play a role in the
fusion protein folding and due to their absence in the APYB36GFP, proper folding is
either hindered or enhanced thereby leading to a difference in proportion of apoptotic
cells. Proline residues are widely recognized as playing a special role in folding and
unfolding transitions of globular protein molecules. But whether prolines help in
stabilizing protein folding or results in its destabilization, is still not clear. Prolines were
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initially shown to destabilize folded conformations (Levitt, 1981). Later studies have
shown that proline residues are important for proper protein folding (Kusano et al., 2001).
Proline residues are shown to have opposite effects on fast and slow protein folding
phases (Osvath et al., 2003). Therefore lack of many proline residues in the APYB36GFP
might be the likely explaination behind the cell cycle arrest and apoptosis differences.
X-ray crystallography of the purified fusion proteins would provide us with more insight
into the three dimensional structure of these proteins and the possible role of the proline
alanine rich sequence in the protein conformation.
It is also likely that these proline residues are important for interaction of YB-1
with some other cell cycle proteins, which eventually help in mediating the apoptosis.
Further on, in the next set of experiments, we show an interaction between the
APYB77GFP / APYB26GFP proteins and Cyclin D1 and propose that the cells get
blocked at the G2/M phase of cell cycle due to this interaction. Construction of a fusion
protein with only the proline alanine rich sequence missing from APYB36GFP can throw
light on the hypothesized importance of this sequence. Further experiments with serial
deletion mutants of the YB-1 N-terminal sequence can provide further knowledge about
the minimal YB-1 sequence/residues required for cell cycle arrest and apoptosis. Our
final conclusion from this part of the project is that the amino-end domain of YB-1 is
involved in regulating cell proliferation.
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Chapter 3. YB-1 Interacts with Cyclin D1 in the Cytoplasm of Cells in G2/M Phase
of Cell Cycle
3.1 Introduction
Protein-protein interactions are intrinsic to virtually all cellular processes. Proteins
rarely function individually and it has been proposed that all proteins in a given cell are
connected with other proteins through an extensive network, where non-covalent
interactions continuously associate and dissociate. Finding interactions between proteins
involved in common cellular functions is a way to get a broader view of how they work
cooperatively in a cell. YB-1 protein during its life span associates with many proteins,
like transcription factors, RNA binding proteins, viral proteins and DNA repair proteins
to yield functionally positive or negative influences.
It is likely that one of the mechanisms by which YB-1 is involved in cell
proliferation is by its binding with one or more cell cycle proteins. Several cell cycle
regulated genes contain Y-box binding sequence in their promoter or enhancer regions
(Ladomery et al., 1995). YB-1 protein has already been shown to interact with some cell
cycle proteins. For example, YB-1 interacts with p53 and this interaction is responsible
for regulating the p53 gene expression (Okamoto et al., 2000). p53 has been shown to be
involved in regulating centrosome duplication (Deng et al., 2000) and it is interesting to
note that YB-1 also associates with the centrosome in mitotic cells (Janz et al., 2002;
Bergmann et al., 2005).
By disrupting one allele of chicken YB-1 gene in DT-40 cells we reported many
phenotypic and morphological abnormalities in the heterozygous mutants (Swamynathan
et al., 2002). One striking difference between the wild type and mutant cells was
downregulation of cyclin dependent kinase inhibitor, p21, in the mutant cells. p21 was
shown to bind to and inhibit the activity of cyclin D1/CDK4 complex thus regulating cell
cycle progression (Cheng et al., 1999; Gladden et al., 2005). Many groups have
elucidated the involvement of YB-1 with cyclins at different levels of regulation
including transcriptional and translational regulations. YB-1 contributes to transcriptional
regulation of cyclin A and cyclin B1 genes (Jurchott et al., 2003). YB-1 knockout by
siRNA in ovarian cancer cells upregulates cyclin B gene expression (Basaki et al., 2007).
YB-1 binds to cyclin D1 mRNA resulting in its translational regulation (Evdokimova et
al., 2006). Decreasing the levels of YB-1 protein by shRNA results in a decrease of
cyclin D1 protein levels (Schittek et al., 2007). However, no study has shown a direct
interaction of YB-1 with the cyclins at the protein level.
Cyclins are a family of proteins, involved in the progression of the cells through
cell cycle. They are key regulators of cell cycle transition, whose abundance varies
through cell cycle (Deanna et al., 1999). They were first identified in marine invertebrates
as proteins whose accumulation and degradation oscillated during the cell cycle
(Rosenthal et al., 1980). There are multiple cyclins like cyclin A, B1, C, D1, D2, D3, E,
F, G, H, K and T, each with a specific function.
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D type cyclins (cyclins D1, D2 and D3) are regarded as essential links between cell
environment and the core cell cycle machinery. Among all cyclin classes, these are the
only ones that stand out as a very unique component of the cell cycle apparatus. Unlike
other cyclins that fluctuate periodically during cell cycle progression, the extracellular
environment controls D type cyclin levels. Thus, D type cyclins are induced by the
mitogenic stimulation and their levels decline when the mitogens are withdrawn (Sherr et
al., 1999). Their levels are also likely to be regulated by cell cycle dependent events
(Stacey 2003).
The manner in which mammalian D type cyclins promote progression of cell cycle
has lately been a topic of intense investigation. The D type cyclins form the regulatory
subunit of the CDK4/6 kinase and function as critical mitogenic sensors that integrate the
growth factor-initiated signals with cell cycle progression (Marshall, C., 1999). Most
cells synthesize more than one D-type cyclin and certain cell types like epithelial cells in
the mammary glands of pregnant mice depend almost exclusively on Cyclin D1 for their
proliferation (Sicinski et al., 1995; Fantl et al., 1995). At the time of their discovery the
D-type cyclins were immediately recognized to be growth factor responsive genes
(Matsushime et al., 1991).
Cyclin D1, which is a prototype of the cyclin gene family, was independently
identified through its ability to rescue G1 cyclin-deficient yeast strains (Xiong et al.,
1991) and it was targeted at the breakpoints of chromosomal translocations in cancer
cells, implicating it as a proto-oncogene (Motokura et al., 1991). Of the three D-type
cyclins, cyclin D1 remains the most extensively studied, largely because of its frequent
overexpression in human malignancy. It is encoded by the Bcl-1 gene and is an essential
regulator of cell cycle progression. Aberrant induction of cyclin D1 activity is reported
and well established in many human tumors (Peters, G., 1994; Gillett et al., 1994; Hall et
al. 1996; Palmero et al., 1996; Arnold, A., 1995; Sherr, C.J., 1996 and 2000; Sherr et al.,
2002; Diehl et al., 2002). It is shown to exert its effects on cell proliferation by
integrating external signals (e.g., mitogens), with the cell cycle machinery (Peters, G.,
1994; Palmero et al., 1996; Sherr, C.J., 1996 and 2000; Diehl et al., 2002; Lukas et al.,
1996; Brown et al., 1998; Roussel et al., 1995).
Cyclin D1 expression is regulated by multiple mechanisms, including, transcription
(Albanese et al., 1995; Winston et al., 1996), its own protein stability (Matsushime et al.,
1991; Hashemolhosseini et al., 1998; Agami et al., 2000; Casanovas et al., 2000;
Miyakawa et al., 2001; Guo et al., 2002), message turnover (Hashemolhosseini et al.,
1998; Dufourny et al., 2000; Lin et al., 2000) and nucleocytoplasmic transport of the
transcript and the protein (Rosenwald et al., 1995; Topisirovic et al., 2003). Cyclin D1
transcription is generally stimulated as a delayed early response to mitogenic signaling
cascades (Sherr, C.J., 1995 and 1996). Its protein stability is regulated through the
glycogen synthase kinase 3β -signal transduction pathways to coordinately enhance
accumulation of cyclin D1 protein (Diehl et al., 1997 and 1998). Once synthesized cyclin
D1 interacts with and activates CDK4 and CDK6 (Meyerson et al., 1994; Matsushime et
al., 1992). CDK4/6-cyclin D1 complexes are both rate limiting and required for cell cycle
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progression. Thus, the intricate regulation of cyclin D1 expression and activity plays a
critical role in ordered progression of cells through the cell cycle.
Cyclin D1 was shown to be one of the key regulators of G1/S transition (Johnson et
al., 1999; Massague et al., 2004; Kastan et al., 2004). However, the expression levels of
cyclin D1 in the G2 phase determine the fate of the next cell cycle (Guo et al., 2005). If
Ras activity is abrogated for any reason during the S/G2 phase, Cyclin D1 induction
during the G2 phase is suppressed and the cells get arrested immediately after mitosis,
due to insufficient levels of cyclin D1 for entry into the subsequent S phase (Hitomi et al.,
1999). Thus, even though cyclin D1 is important for the G1/S transition of cells (Baldin
et al., 1993; Lukas et al., 1995; Ohtsubo et al., 1995), it is absolutely essential at the G2
phase for the cells to decide to complete the next division cycle (Hitomi et al., 2001;
Stacey, 2003).
Striking similarities exist between YB-1 and cyclin D1. The levels of both proteins
are upregulated in a variety of neoplasms (Kohno et al. 2003; Fu et al. 2004) including
primary breast cancers, osteosarcomas, ovarian cancers, lung cancers, colon cancers,
synovial sarcomas and parathyroid adenomas. They show similar cellular localization at
the G2 phase of cell cycle. Although YB-1 is classified as a cytoplasmic protein and
cyclin D1 a nuclear protein (Baldin et al., 1993), YB-1 is found in the nucleus in mid G1
phase to S phase (Jurchott et al 2003) at the same time with cyclin D1. Cyclin D1
relocates to the cytoplasm after the end of S phase progressing to the G2 phase (Stacey
2003; Gou et al., 2005), when YB-1 is also mostly concentrated in the cytoplasm. Cyclin
D1 protein levels increase in G2 phase and are maintained through mitotic and G1 phases
before its level goes down in the S phase. In fact the levels of cyclin D1 at the G2/M
phase of cell cycle are crucial for the cells to decide if they can undergo another round of
replication. Cyclin D1 nuclear import plays a very critical role in cardiomyocyte
proliferation (Tamamori-Adachi et al., 2003). Levels of YB-1 also play a role in deciding
if the cell has to undergo further replication, as inferred from the heterozygous mutant
DT40 cells (Swamynathan et al. 2002) which showed 4n, 6n and 8n DNA content
suggesting that the cells undergo DNA replication but not cell division (replicative
senescence). YB-1 is shown to be involved in apoptosis (Swamynathan et al., 2002;
Schittek et al., 2007). Data from the three YB-1 N-terminal protein internalization
analysis also implicates YB-1 in apoptosis. Similarly cyclin D1 is also implicated in cell
apoptosis (Hiyama et al., 1999; Duquesne et al., 2001).
The objectives of the current study are to determine if YB-1 interacts with any of
the cyclins at the protein level and if so, to initiate a preliminary investigation to
understand the details of this interaction.
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3.2 Materials and methods
3.2.1 Antibodies and reagents
All the chemical reagents, unless otherwise specified were purchased from SigmaAldrich (St. Louis, MO). The Minimum essential medium (cat # 11095-080), Dulbecco’s
modified medium (cat # 1965-092), Penicillin-Streptomycin (cat # 15140-148) and
Trypsin-EDTA (cat # 25300) was obtained from Invitrogen-Gibco (Carlsbad, CA). The
YB-1 polyclonal antibody (10mg/ml) was generated for our lab by Sigma. The antibodies
against all the cyclins (cat # RB212-P1, RB-008-P1, RB-1548-P1 and MS-221-P1,
1mg/ml) were obtained from Labvision (Fremont, CA). The antibody against GFP (cat #
A11122, 2 mg/ml) and the fluorescent-labeled secondary antibodies (cat #s A21429 and
A11029, 2mg/ml) were from Invitrogen-Molecular probes (Carlsbad, CA). The lamin
antibody (cat # 612162, 250 μg/ml) was from BD Biosciences (San Jose, CA). The
chemiluminescence western blot developing solution kit (cat # 34080) and the BCA
protein assay kit (cat # 23225) was from Pierce (Rockford, IL). The Vectashield
Mounting Medium containing DAPI (cat # H-1200) was from Vector laboratories
(Burlingame, CA). The protein A Sepharose beads (cat # 17-0780-01) were from
Amersham Biosciences (Piscataway, NJ).
3.2.2 Cell culture
Rat Hepatoma cells (ATCC-H-411E) were grown in monolayers in Minimum
Essential medium supplemented with 10% FBS, 100U/ml Penicillin, 100 μg/ml
Streptomycin and 5% CO2 : 95% air, in a humidified incubator maintained at 37°C. Cells
were subcultured 1:5 at confluency with 0.05% trypsin-EDTA. Cell synchronization at
G1/S phase was done using a double thymidine block with 2mM thymidine as described
previously (Smits et al., 2000). G2/M phase synchronization was done with 2.5 μg/ml
nocodazole for 24 hrs. The cell synchronizations were confirmed by FACS analysis.
Inhibition of YB-1 phosphorylation was done by incubating cells with 0.4 μM
wortmannin for 24 hrs as described previously (Evdokimova et al., 2006). Inhibition of
the cyclin D1 phosphorylation was done by incubating cells with 20 mM LiCl for 24 hrs.
as described previously (Diehl et al., 1998).Transcriptional block was provided by
incubating cells with 2 μg/ml actinomycin for time periods ranging from 30 min. to 24
hrs.
3.2.3 FACS analysis
For confirmation of successful synchronization and cell cycle analysis,
synchronized cells were harvested by trypsinization or scraping on ice and pelleted down
at 500 g for 5 min. The pellets were washed with PBS, cells were fixed with ice cold 70%
EtOH, incubated on ice for 45 min. and pelleted down at 500 g for 5 min. The pellets
were washed with Hanks Balanced Salt Solution (HBSS) containing 1% BSA. The
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resulting pellets were resuspended in Propidium Iodide buffer (1:1 dilution of 20ug/ml of
PI in HBSS and 1 mg/ml RNAse A) and incubated for 30 min. in a 37°C water bath.
Samples were analyzed using a Becton Dickinson FACS Calibur.
3.2.4 Immunoprecipitation and immunoblotting
After trypsinization, harvested cells were centrifuged at 500 g. The pellets were
washed with ice cold PBS, and processed either for whole cell extract preparation or
nuclear and cytoplasmic extracts preparation. For whole cell extract preparation, the
pellets were lysed in Ripa buffer (10 mM Tris-HCl pH-7.4, 5mM EDTA, 150 mM NaCl,
1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100), supplemented with freshly
added protease inhibitors (1 μg/ml leupeptin, 1μg/ml aprotinin and 1mM PMSF).
Samples were kept on ice for 5 min. and then sonicated at Branson 4 settings for 8 cycles
of 15 sec. each with intermittent chilling on ice. The lysates were then stored on ice for
30 min., clarified by high-speed centrifugation at 8000 g for 5 min. at 4°C and the
supernatant was used as whole cell extracts. For nuclear and cytoplasmic fractionation,
the cell pellets were resuspended in Buffer A (50 mM NaCl, 10 mM HEPES pH-8.0, 500
mM sucrose, 1mM EDTA, 0.2% Triton-X-100, freshly added protease inhibitors
mentioned above and 7mM β-Mercaptoethanol), vortexed at high speed for 45 sec., spun
down at 2000 g for 2 min. at 4°C and the supernatant was stored as cytoplasmic extract.
The pellets were resuspended gently in Buffer B (50 mM NaCl, 10 mM HEPES pH-8.0,
25% glycerol, 0.1 mM EDTA, protease inhibitors and 7mM β-Mercaptoethanol), spun
down at 2000 g for 2min. at 4°C and the supernatant was discarded. Resulting pellets
were resuspended in Buffer C (350 mM NaCl, 10 mM HEPES pH-8.0, 25% glycerol, 0.1
mM EDTA, protease inhibitors and 7mM β-Mercaptoethanol) and incubated on ice for
30 min. with intermittent high-speed vortexing, spun down at 11000 g for 15 min at 4°C.
The resulting supernatant was stored as nuclear extract. All samples were stored at –80°C
until use. 200 μl aliquots of either the whole cell extracts or the nuclear and cytoplasmic
extracts were diluted to 500 μl in appropriate buffers and used for immunoprecipitation.
In short equivalent amounts of whole cell lysates or nuclear and cytoplasmic extracts
were incubated with 1:1000 dilution of YB-1/cyclin D1 antibody or 1:2000 dilution of
GFP antibody overnight at 4°C on a rocker. The next day equal amount of Protein A
Sepharose beads were added to each sample and incubated for 2 hrs. at room temperature
on a rocker. The beads were pelleted down at 8000 g for 4 min. and the pellet was
washed with lysis buffer twice. The resulting pellet was resuspended in equal amounts of
sample buffer and loaded onto 12% SDS-PAGE gels. Primary antibody at the dilution of
1:2000 for YB-1/cyclin D1/lamin and 1:7500 dilution for GFP was used for incubation of
blots overnight at 4°C and secondary antibody at 1:5000 dilution for YB-1/cyclin
D1/lamin and 1:15000 dilution for GFP for 1 hr. at room temperature. The blot was
developed using chemiluminescence (SuperSignal West Pico Chemiluminescent
Substrate) according to the manufacturers protocol.
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3.2.5 Quantitation of immunoblotting data
All images were scanned and exported as TIFF files to Adobe Photoshop software
(San Hose, CA) for subsequent analysis. Each image was adjusted to invert the scale. A
box was drawn around the biggest band using Marquee tool and histogram analysis was
done. The mean was noted down and then the same box was used to drag down to
another band to repeat the process. For each band, representative integrated density
values were computed after subtracting the background density. This gave the exact
intensity of each band. Mean integrated density values from three independent
experiments were calculated and these values were used to draw graphs using Microsoft
Excel programming. Statistical analysis of the mean intensity data was performed using
the Student’s t test using the GraphPad software and results were considered statistically
significant if the P value of <0.002 was reached.
3.2.6 Immunocytochemistry and indirect immunofluorescence
For immunocytochemistry, cells were plated on cover slips. After each time point,
cells were rinsed twice with PBS, fixed with 4% p-formaldehyde for 15 min., washed
with PBS twice and stored at 4°C, until all time point samples had been collected. The
cells were blocked with 5% goat serum and 3% BSA in PBS for 30 min. and rinsed with
PBS thrice. Cells were then incubated with primary antibodies (Mouse-YB-1 (1:300),
Rabbit Cyclin D1 (1:500), Rabbit pSER (1:500) and Rabbit Lamin (1:500)) for 3 hrs. and
rinsed with PBS thrice. Then the cells were incubated with secondary antibodies - FITC
conjugated Anti-Rabbit IgG (1:500) and Texas-Red conjugated Anti-Mouse IgG (1:500)
for 1 hr. in the absence of light. The coverslips were rinsed with PBS thrice, once with
water to remove any salts and left to air-dry for 45 min. in absence of light. The
coverslips were mounted onto glass slides using Vectashield Mounting Medium
containing DAPI to counter stain nuclei. The slides were stored at -20°C until analyzed
by confocal microscopy.
3.2.7 Confocal microscopy
Confocal images were captured using LSM 510 confocal laser-scanning three-color
microscope (Carl Zeiss, Jena, Germany). Images were captured using the Argon laser at
75% output and HeNe1 laser at excitation wavelengths 488 nm and 543 nm respectively.
Optical slice thickness was set to 0.3 μm, magnification to 100x and sections presented
were taken approximately at mid height level of cells. Photomultiplier gain and laser
power were identical within each experiment. A minimum of 100 stained cells were
scored for each experiment reported. The images were analyzed and adjusted for contrast
in Adobe Photoshop 5.0 (San Jose, CA).
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3.2.8 Quantitation of immunofluorescence data
Each stack of confocal images were imported and opened on the LSM image
scanner. The histogram analysis was performed on atleast 4 cells from each slice and
atleast 5 slices for each experiment and all the slices were analyzed for the same cells. To
start with, the outlining tool was used to demarcate each cell area. The brightness contrast
feature was used to minimize one colour and the total pixel count was noted down for the
other colour. Then the first colour was restored back to the default setting and the colocalization coefficient for channel one was noted down. This gave the % of colocalized
pixels of one colour with the other. The total number of colocalized pixels were then
calculated. Averages of the total pixels and the colocalized pixels were determined. The
average % of total colocalized pixels was then calculated by comparison of the average of
total pixels vs. the average of colocalized pixels. This gave us the % co-localization of
the first protein to the second protein. Similarly the % co-localization of the second
protein with the first was also calculated.
3.3 Results
3.3.1 Interaction of YB-1 with Cyclin D1
Earlier studies show that YB-1 regulates transcription of two cyclins i.e. cyclins A
and B1 (Jurchott et al., 2003). YB-1 was also shown to translationally regulate cyclin D1
mRNA (Evdokimova et al., 2006). To investigate if YB-1 shows an interaction with any
of the cyclins at a protein level, we performed co-immunoprecipitation assays on whole
cell extracts of exponentially growing rat hepatoma cells with antibodies against various
cyclins (A, B1, D1 and D2) and YB-1 and YB-2 respectively. Equal amounts of
immunoprecipitated samples were blotted on a 12% SDS-PAGE denaturing gel and
probed for presence of YB-1 or the respective cyclins. We detected a signal for YB-1 in
the cyclin D1 immunoprecipitated sample (Fig. 3.1) but not in samples
immunoprecipitated with the three other cyclin antibodies. YB-1 immunoprecipitated
sample was used as a positive control and YB-2 immunoprecipitated sample as an
experimental negative control. Cell lysates incubated with the beads in absence of any
antibodies were used as an internal negative control, to rule out any non-specific signals.
Reciprocal blots by immunoprecipitation with YB-1 antibody and probing for the abovementioned cyclins confirmed immunoprecipitation of YB-1 only with cyclin D1 and vice
versa (data not shown). The same results were also confirmed in rat aortic smooth muscle
(RASM) cells (data not shown). These results indicate that YB-1 protein interacts with
cyclin D1.
3.3.2 YB-1 co-localizes with Cyclin D1 predominantly at the G2/M phase
YB-1 is predominantly a cytoplasmic protein and only about 5% of the total YB-1
is localized in the nucleus of exponentially growing cells (Jurchott et al., 2003). Initial
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Fig. 3.1 YB-1 and Cyclin D1 co-immunoprecipitate with each other in rat
hepatoma cells
Whole cell extracts of exponentially growing unsupplemented rat hepatoma cells were
immunoprecipitated with antibodies against cyclin A, B1, D1 and D2. The resulting
samples were analyzed by immunoblotting for the presence of YB-1 using a polyclonal
YB-1 antibody. YB-1 signals were detected only with YB-1 antibody (+ve control) and
cyclin D1, but not with YB-2 (-ve control) or the other cyclins and vice versa (data not
shown), suggesting that TYB-1 interacts with only cyclin D1 among the tested cyclins.
This co-immunoprecipitation was also confirmed in Rat aortic smooth muscle cells (data
not shown).
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studies indicated that cyclin D1 is localized predominantly in the nucleus of
asynchronously growing cells (Baldin et al., 1993). However, later studies showed
subcellular localization of cyclin D1 to oscillate during the cell cycle (Lukas et al., 1994;
Diehl et al., 1998). Owing to this differential distribution of both proteins in the subcellular compartments through the cell cycle, we proceeded to investigate the relative
distribution of YB-1 and cyclin D1 in the nucleus and cytoplasm of cells at different
phases of cell cycle. For this purpose, G1/S and G2/M phase synchronization of cells was
done. Double thymidine block, which inhibits DNA replication by inhibiting the
conversion of CDP to dCDP, was used to render a G1/S phase block as described
previously (Smits et al., 2000). G2/M phase synchronization was done using the drug
nocodazole, which causes microtubule depolymerization, thus blocking the cells in prometaphase and thereby rendering the G2/M phase block. The % of synchronized cells
was estimated by FACS analysis to ensure that majority of the cell population got
synchronized at the respective phases (Fig. 3.2 and 3.3), before any further steps were
performed.
Immunocytochemistry and indirect immunofluorescence / co-localization analysis
was performed on these synchronized cells. For this purpose, unsynchronized and
synchronized cells were fixed onto coverslips and labeled for YB-1 and Cyclin D1 as
mentioned previously. The relative localizations of YB-1 and cyclin D1 in the nucleus
and cytoplasmic compartments of these cells were detected by confocal microscopy. In
the unsynchronized control and G1/S phase synchronized cells, YB-1 was present
predominantly in the cytoplasm (Fig. 3.4, panels A and D) whereas cyclin D1 was
predominantly in the nucleus (Fig. 3.4, panels C and F). In both cases minimal colocalization of YB-1 and cyclin D1 was seen in both nucleus and cytoplasm. In stark
contrast, the distribution and co-localization pattern of the two proteins in G2/M phase
blocked cells showed a drastic change. Negligible amounts of YB-1 and cyclin D1 were
detected in the nucleus of the G2/M phase blocked cells (Fig. 3.4, panels G and I). Most
of the YB-1 and cyclin D1 was detected in the cytoplasm (Fig. 3.4, panels G and I) and
their co localization was very predominant as evidenced by the yellow dots seen in the
overlap of both the images, when compared to the wild type and G1/S phase blocked
cells (Fig. 3.4, compare panels B and E with H).
In order to confirm this result, co-immunoprecipitation and immunoblot analysis of
unsynchronized and G2/M phase synchronized cells was performed. Nuclear,
cytoplasmic and nuclear + cytoplasmic fractions were used for the analysis. The nuclear
+ cytoplasmic fractions were used in lieu of whole cell extracts to investigate if the YB-1
cyclin D1 interaction occurs post-lysis of cells. In case of unsynchronized cells, we
detected YB-1 signals mainly in cytoplasmic or nuclear + cytoplasmic samples
immunoprecipitated with YB-1 (Fig. 3.5, left). Cyclin D1 was detected mainly in the
nuclear and nuclear + cytoplasmic samples, immunoprecipitated by cyclin D1. This
suggested that in unsynchronized cells, YB-1 is predominantly present in the cytoplasm,
whereas Cyclin D1 is in the nucleus. In the nocodazole treated (G2/M phase blocked)
cells, no signal was detected for either YB-1 or Cyclin D1 in the nuclear extracts,
confirming our previous result. We detected both YB-1 and cyclin D1 in cytoplasmic and
cytoplasmic + nuclear samples immunoprecipitated with either of the antibodies (Fig. 3.5
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Fig. 3.2 Synchronization of cells at the G1/S phase of cell cycle by a double
thymidine block
Rat hepatoma cells were blocked at the G1/S phase of cell cycle by a double thymidine
block. FACS analysis performed on the cells confirms that a major proportion of cells are
blocked at the G1/S phase of cell cycle.

Fig. 3.3 Synchronization of cells at the G2/M phase of cell cycle by a nocodazole
block
Rat hepatoma cells were blocked at the G2/M phase of cell cycle by a nocodazole block.
FACS analysis performed on the cells confirms that a major proportion of cells are
blocked at the G2/M phase of cell cycle.
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Fig. 3.4 Co-localization of YB-1 and Cyclin D1 in G2/M phase
Exponentially growing unsynchronized and G1/S phase synchronized cells with a double
thymidine block or G2/M phase synchronized cells with a nocodazole block grown on
coverslips were fixed with 4% p-formaldehyde and blocked with 3% goat serum and
BSA. The cells were then labeled with primary antibodies against YB-1 and cyclin D1
and secondary antibodies conjugated to FITC or Texas Red respectively. Distribution of
YB-1 and cyclin D1 in these cells was analyzed by confocal microscopy. We detected the
presence of both YB-1 and cyclin D1 predominantly in the cytoplasm of nocodazoleblocked cells where they co-localized with each other (panels G to I), as evidenced by the
yellow dots where FITC and Texas Red overlap. In control (panels A to C) and double
thymidine-blocked cells (panels D to F) cyclin D1 was seen in both nucleus and
cytoplasm and YB-1 in the cytoplasm with minimal co-localization between the two
suggesting that YB-1 colocalization with cyclin D1 is predominant only in the cytoplasm
of cells in G2/M phase of cell cycle.

59

60

Fig. 3.5 Interaction of YB-1 with Cyclin D1 and vice-versa is seen predominantly at
the G2/M phase of cell cycle
Nuclear (N), cytoplasmic (C) and nuclear + cytoplasmic (N+C) extracts of exponentially
growing unsynchronized G2/M phase synchronized cells were immunoprecipitated with
antibodies against YB-1 or cyclin D1 and analyzed by western blotting to investigate the
total % of immunoprecipitation of YB-1 with cyclin D1 and vice versa from each of the
above mentioned extracts. A representative blot of immunoprecipitation and immunoblot
analysis is hown here. We show that YB-1 immunoprecipitates with Cyclin D1 and vice
versa predominantly in the cytoplasmic and nuclear + cytoplasmic extracts of only the
G2/M phase blocked cells confirming the results got by immunocytochemistry and
immunofluorescence analysis shown in Fig. 3.4.
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right side), confirming the results of immunocytochemistry and co-localization
experiments. These results suggest that YB-1 and Cyclin D1 interact and co-localize in
the cytoplasm of G2/M phase blocked cells.

3.3.3 Quantitative interaction of YB-1 with Cyclin D1 and vice versa
Having demonstrated the interaction and co-localization of YB-1 and cyclin D1 in
the cytoplasm of G2/M phase blocked cells, we proceeded to measure the quantitative
interaction between both the proteins in unsynchronized and G2/M phase synchronized
cells. In order to determine the total amount of pull down of YB-1 with cyclin D1
antibody and vice versa as compared to immunoprecipitation by its own antibody,
co-immunoprecipitation and immunoblot analysis were performed as previously. Three
independent experiments were performed for statistical analysis. The intensity of the
signals was calculated and the mean integrated intensity from three experiments is
reported in Fig. 3.6.
As expected, in the control unsynchronized cells, very faint signals for YB-1 in the
nuclear extracts and cyclin D1 in the cytoplasmic extracts were detected. About 5-7% of
total YB-1 and cyclin D1 immunoprecipitation was seen with the cyclin D1 and YB-1
antibodies in the nuclear + cytoplasmic fractions (Fig. 3.6). About 80% of the total YB-1
(total YB-1 = YB-1 immunoprecipitated with its own antibody, which is normalized to
read 100%) immunoprecipitated with Cyclin D1 antibody and vice versa in the
cytoplasmic and cytoplasmic + nuclear fractions of the G2/M phase synchronized cells
(Fig. 3.6). In contrast negligible amounts of either protein were detected in the nuclear
fractions. Using the student’s t-test the p value for these calculations was determined to
be < 0.0019, which is considered statistically significant.
We then quantitated the % co-localization of YB-1 and cyclin D1 in control and
nocodazole treated cells from the immunofluorescence confocal images as mentioned in
the methods. The results obtained are very similar to the immunoblotting quantitation
data (Tables 3.1 and 3.2). This reinforces our previous conclusion that YB-1 and cyclin
D1 interaction is predominant in the cytoplasm of cells in the G2/M phase of cell cycle.
3.3.4 N-terminus of YB-1 is involved in the interaction of YB-1 with Cyclin D1
After demonstrating the interaction of cyclin D1 with full length YB-1 protein, we
proceeded to investigate the involvement of the N-terminal domain of YB-1 in this
interaction. Most proteins are composed of multiple modular interacting domains.
Typically, protein interaction domains are independently folding modules of a short
stretch of amino acids, which can be expressed in isolation from host proteins while
retaining their intrinsic ability to bind their physiological partners. From our previous
study (as shown in chapter 2), we had three YB-1 N-terminal proteins, APYB26GFP,
APYB36GFP and APYB77GFP, each containing a short stretch of amino acids in fusion
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Fig. 3.6 YB-1 immunoprecipitates approximately 80% of the total Cyclin D1 and
vice versa at the G2/M phase of cell cycle
The mean integrated intensity of the blot signals from three independent experiments of
co-immunoprecipitation and immunoblot analysis of unsynchronized and G2/M phase
synchronized cell’s nuclear and cytoplasmic extracts shows that approximately 80% of
the total YB-1 got immunoprecipitated with cyclin D1 antibody and vice versa in the
cytoplasmic and cytoplasmic + nuclear fractions of the G2/M phase synchronized cells.
Faint signals were seen in the nuclear extracts or in unsynchronized cell extracts,
suggesting that YB-1 cyclin D1 interaction is predominant in the cytoplasm of G2/M
phase cells.
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Table 3.1 Quantitative co-localization of YB-1 with Cyclin D1 and vice versa in
control cells

Cell % YB-1 overlapping CyclinD1 % Cyclin D1 overlapping YB-1
#
(FITC overlapping Texas Red) (Texas Red overlapping FITC)
1

7.95

8.10

2

7.22

8.21

3

8.90

8.07

4

6.41

5.85

We detected minimal co-localization of YB-1 with cyclin D1 and vice versa in control
cells by quantitation of the immunocytochemistry data.

Table 3.2 Quantitative co-localization of YB-1 with Cyclin D1 and vice versa in
nocodazole blocked cells

Cell % YB-1 overlapping CyclinD1 % Cyclin D1 overlapping YB-1
#
(FITC overlapping Texas Red) (Texas Red overlapping FITC)
1

69.37

76.46

2

74.52

79.74

3

79.28

83.29

4

79.44

81.95

A very high % of co-localization of YB-1 with cyclin D1 and vice versa was detected in
nocodazole blocked G2/M phase cells by quantitation of the immunocytochemistry data.
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with an antennapedia and GFP sequence and a control clone APGFP lacking any YB-1
sequence. In order to determine if the YB-1 N-terminal proteins interact with cyclin D1,
rat hepatoma cells were incubated with 40 μg/ml of the four fusion proteins as described
previously for 3 and 18 hrs. Whole cell extracts of unsynchronized and G2/M phase
synchronized cells were incubated with GFP antibody for immunoprecipitation of the
internalized fusion proteins and probed with cyclin D1 antibody for analysis of any cyclin
D1 immunoprecipitated along with the fusion proteins. As a positive control, cyclin D1
immunoprecipitated with YB-1 antibody was used on the same blot. APGFP, which does
not have any YB-1 sequence, acted as our negative control. In unsynchronized cells
cyclin D1 band was not detected with GFP in any of the APYBGFP or APGFP incubated
cells (Fig. 3.7). However, in nocodazole-blocked cells, cyclin D1 band was detected at
both 3 hrs. and 18 hrs. with APYB26GFP and APYB77GFP incubated cells (Fig. 3.7).
This suggests that YB-1 N-terminal sequence is involved in its interaction with cyclin D1
in cells at the G2/M phase of cell cycle. The cyclin D1 signal however was not detected
in case of APYB36GFP incubated cells, suggesting that the YB-1 N-terminal sequence
present in this clone is either not sufficient or not accessible to interact with cyclin D1.
These experiments suggest that the proline rich YB-1 N-terminal sequence is sufficient
for immunoprecipitation of cyclin D1 in G2/M phase synchronized rat hepatoma cells.
3.3.5 Inhibition of YB-1 phosphorylation by Wortmannin results in re-localization of
Cyclin D1 in the nucleus even after nocodazole block
Dynamic protein-protein interactions are frequently regulated by post-translational
modifications, most notably phosphorylation. Eukaryotic cells widely use reversible
phosphorylation to regulate protein-protein interactions to transmit and integrate signals
received from their environment (Pawson, 2004). YB-1 is reported to be phosphorylated
mainly by the PI3K-Akt pathway (Sutherland et al. 2005). Wortmannin acts as a
pharmacological inhibitor of the PI3K cycle (Evdokimova et al., 2006). In order to
investigate if the predominant presence of cyclin D1 in cytoplasm after nocodazole
blocking is dependent on the phosphorylation state of YB-1, cells grown on coverslips
were incubated with nocodazole and wortmannin simultaneously for 24 hrs. and
analyzed. We detected a significant amount of cyclin D1 in the nucleus after
simultaneous treatments with nocodazole and wortmannin (Fig. 3.8, panel L). YB-1 was
detected only in the cytoplasm, especially in the perinuclear space after incubation with
only nocodazole or both nocodazole and wortmannin (Fig. 3.8, panels D and J).
Wortmannin treatment alone did not result in any change in the pattern of distribution of
either YB-1 or cyclin D1 (Fig. 3.8, Panels G and I) as compared to the control cells (Fig.
3.8, panels A to C). Therefore the presence of cyclin D1 in the nucleus can be attributed
to incubation with both nocodazole and wortmannin. These results were reproduced and
confirmed by western blotting (data not shown). This led us to hypothesize that
translocation of cyclin D1 from the nucleus to cytoplasm in the G2/M phase of cells may
be dependent on the phosphorylation state of YB-1.
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Fig. 3.7 APYB26GFP and APYB77GFP immunoprecipitate Cyclin D1 in G2/M
phase blocked rat hepatoma cells
Whole cell lysates of unsynchronized and G2/M phase synchronized cells, incubated with
40 μg/ml of the three APYBGFP and APGFP proteins for 3 and 18 hrs. were
immunoprecipitated with GFP antibody and resulting samples were analyzed for the
presence of cyclin D1 and GFP with their specific antibodies. Immunoprecipitation of
cyclin D1 from nocodazole blocked cells with YB-1 antibody was used as a +ve control
for cyclin D1 and immunoprecipitation of unincubated cells with GFP antibody was used
as a –ve control for both GFP and cyclin D1. Cyclin D1 band was not detected in any
samples from unsynchronized cells. We detected cyclin D1 signals in lysates from G2/M
phase synchronized cells incubated with APYB26GFP and APYB77GFP proteins, but
not with APYB36GFP and APGFP, indicating that the 26 amino acid proline rich
sequence from YB-1 N-terminus is necessary and enough for binding with cyclin D1 at
the G2/M phase of cell cycle in rat hepatoma cells.
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Fig. 3.8 Inhibition of YB-1 phosphorylation by Wortmannin resulted in relocalization of Cyclin D1 in the nucleus even after nocodazole block
Exponentially growing cells on coverslips were incubated with wortmannin and/or
nocodazole for 24 hrs. and analyzed by immunocytochemistry and indirect
immunofluorescence with antibodies against YB-1 and cyclin D1 to investigate the
effects of wortmannin incubation on the co-localization of the two proteins in
unsynchronized and G2/M phase synchronized cells. Cells treated with only wortmannin
showed cyclin D1 in both nucleus and cytoplasm (panel I) and YB-1 in the cytoplasm
(panel G) with minimal co-localization (panel H), similar to the distribution of both the
proteins in control cells (panels A to C). Nocodazole treated cells showed both proteins
colocalized together in the cytoplasm (panels D to F). In contrast to this, treatment of
cells with both nocodazole and wortmannin resulted in the presence of cyclin D1 in the
nucleus as well as cytoplasm (panel L), whereas YB-1 was seen predominantly in the
cytoplasm (panel J).
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3.3.6 Inhibition of Cyclin D1 phosphorylation does not change co-localization of
YB-1 with Cyclin D1
Cyclin D1 phosphorylation and nuclear export is mediated by glycogen synthase
kinase - 3β (GSK-3β) association with nuclear exportin CRM1 (Diehl et al. 1998). To
study if inhibition of phosphorylation of cyclin D1 results in a change in co-localization
of YB-1 and cyclin D1, we incubated cells with LiCl, which is an inhibitor of GSK-3β
activity. LiCl was previously found to be particularly efficient for this purpose in rat
hepatoma cells (Lewitt et al., 2001). In unsynchronized and nocodazole blocked cells,
YB-1 and cyclin D1 show similar distribution as described previously (Fig. 3.9, panels A
to F). We did not detect any changes in the pattern of distribution or co-localization of
YB-1 and cyclin D1 in the LiCl and LiCl + nocodazole treated cells (Fig. 3.9, panels G to
L), indicating that cyclin D1 phosphorylation states might not determine its interaction or
co-localization with YB-1. These results were reproduced and confirmed by western
blotting (Fig. 3.10). We conclude that the phosphorylation state of cyclin D1 might not be
important for its co-localization with YB-1 in the cytoplasm of cells in G2/M ohase of
cell cycle.
To rule out the possibility of cytoplasmic predominance of both proteins due to the
breakdown of nuclear membrane, towards initiation of metaphase (the stage at which
nocodazole blocks cell cycle), we checked the integrity of the nuclear membrane by
immunoblotting and indirect immunofluorescence analysis of lamin, which is integral to
the nuclear membrane. The results clearly show lamin only in the nuclear extracts (Fig.
3.11) and the pattern of staining of lamin in both control and G2/M phase blocked cells is
similar (Fig. 3.12). This suggests that the predominant co-localization of YB-1 and cyclin
D1 in the cytoplasm of G2/M phase blocked cells is most likely due to an active transport
of proteins and not just passive diffusion.
3.3.7 YB-1 - Cyclin D1 interaction is not completely mediated by RNA
YB-1 forms an important part of ribonucleoproteins (Skabkin et al., 2004). It is
involved in translational repression of Cyclin D1 by binding to its mRNA (Evdokimova
et al., 2006). To determine if the interaction seen between YB-1 and cyclin D1 is RNA
dependent, we treated rat hepatoma whole cell lysates with 100 μg/ml RNAse A for 2
hrs. prior to immunoprecipitation and then probed for the presence of YB-1 and cyclin
D1. We detected immunoprecipitation of YB-1 with cyclin D1 and vice versa in the
RNAse treated samples as well as untreated samples (Fig. 3.13). We therefore conclude
that this YB-1 - cyclin D1 protein-protein interaction is not mediated through RNA.
3.3.8 YB-1 and Cyclin D1 show a change in distribution pattern after transcriptional
block
YB-1 acts as a transcriptional activator of many genes. Cyclin D1 promoter shows
binding sites for AP-1 (Watanabe et al., 1996; Lee et al., 1999) and NF-κB (Guttridge et
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Fig. 3.9 Inhibition of Cyclin D1 phosphorylation with LiCl did not change the colocalization of YB-1 and Cyclin D1 in G2/M phase blocked cells
Exponentially growing cells on coverslips were incubated with LiCl and/or nocodazole
for 24 hrs. and analyzed by immunocytochemistry and indirect immunofluorescence with
antibodies against YB-1 and cyclin D1 to investigate the effects of LiCl incubation on the
co-localization of the two proteins in unsynchronized and G2/M phase synchronized
cells. Cell treated with only LiCl showed cyclin D1 in both nucleus and cytoplasm (panel
I) whereas YB-1 distribution was seen predominantly in the cytoplasm (panel G) with
minimal co-localization (panel H), similar to the distribution of both the proteins in
control cells (panels A to C). Nocodazole treated cells showed both proteins colocalized
together in the cytoplasm (panels D to F). Treatment of cells with nocodazole and LiCl
also resulted in the presence of both YB-1 and cyclin D1 in the cytoplasm of cells colocalized with each other (panels J to L).
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Fig. 3.10 Immunoblot analysis of nuclear and cytoplasmic extracts of cells
incubated with LiCl and/or nocodazole
A representative blot of the nuclear and cytoplasmic extracts of cells treated with either
nocodazole and/or LiCl, confirms that the cytoplasmic distribution of cyclin in G2/M
phase cells is independent of its phosphorylation state. Cyclin D1 was present only in the
cytoplasmic extracts of nocodazole or nocodazole and LiCl incubated cells whereas it
was mainly seen only in the nuclear extract of LiCl incubated cells.

70

Fig. 3.11 Lamin is seen only in nuclear extracts of cells treated with nocodazole
Western blotting analysis of nuclear and cytoplasmic extracts of cells probed with lamin
showed the lamin signal only in the nuclear extracts of cells suggesting that the nucleus is
intact even after the nocodazole incubation.

Fig. 3.12 Evidence that nocodazole treatment does not cause breakdown of nuclear
membrane
Immunocytochemistry analysis showed similar staining of lamin in both control and
nocodazole treated cells, suggesting that the nuclear membrane integrity is maintained in
nocodazole treated cells.
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Fig. 3.13 YB-1 and Cyclin D1 interaction is independent of mRNA
Immunoblot analysis of RNase treated whole cell extracts show immunoprecipitation of
cyclin D1 with YB-1 indicating the presence of a YB-1 cyclin D1 interaction even in the
absence of mRNA.
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al., 1999; Joyce et al., 1999), STAT (Matsumura et al., 1999), E2F/DP (Lee et al., 2000),
ATF/CREB (Lee et al., 1999; Nagata et al., 2001) and sp-1/sp-3 (Watanabe et al., 1998;
Nagata et al., 2001), but not the inverted CCAAT box repeats to which YB-1 is known to
bind. However this just rules out its direct transcriptional regulation by YB-1. However,
YB-1 was shown to bind to the NF-κB subunit p65 (Raj et al., 1996) and our preliminary
experiments showed an interaction of both YB-1 and cyclin D1 with the NF-κB subunits
p52 and Rel B. Therefore, to explore the possibility of indirect transcriptional regulation
of cyclin D1 by YB-1, exponentially growing rat hepatoma cells were incubated with
actinomycin D for time periods ranging from 30 min. to 24 hrs. Immunocytochemistry
and indirect immunofluorescence analysis were performed on these cells by YB-1 and
cyclin D1 labeling. We noticed a decrease in the levels of nuclear YB-1 and cyclin D1
beginning at the 30 min. time point of incubation (Fig. 3.14, panel B) leading to
negligible nuclear and maximal cytoplasmic detection of both proteins at the 1 and 2 hrs.
time points (Fig. 3.14, panels C and D). Again beginning the 4 hrs. time point and leading
to the 8 hrs. time point, a small amount of both the proteins were seen in the nucleus (Fig.
3.14, panels E and F). The 12 hrs. and 24 hrs. time point slides showed distribution of
cyclin D1 in both nucleus and cytoplasm and YB-1 predominantly in the cytoplasm (Fig.
3.14, panels G and H). Since there was no apparent decrease in the total levels of either of
the proteins, this experiment could not be used to conclude if YB-1 plays a role in
transcriptional regulation of cyclin D1 or not, but we could speculate from the data
derived that the relative subcellular distribution of the proteins is inter-related.
3.4 Discussion
Y-box binding proteins are involved in many cellular functions. Increased
expression of YB-1 has been associated with cell proliferation and transformation
(Bargou et al., 1997). Though YB-1 has been shown to be transcriptionally regulating
some genes associated with cell division and cell cycle, no study has elucidated the direct
mechanism of its regulation of cell proliferation.
Our study for the very first time shows a protein-protein interaction of YB-1 with
the cell cycle protein cyclin D1. Cyclin D1 is an important cofactor for several
transcription factors (Coqueret, 2002; Ewen et al., 2004). To begin with, in this study, we
show co-immunoprecipitation of cyclin D1 with YB-1 and vice versa from crude
unsupplemented whole cell lysates. Co-immunoprecipitation is a classic method of
detecting protein-protein interactions and has been used in literally thousands of
experiments. There are many distinct advantages to analyzing protein-protein interactions
by co-immunoprecipitation studies in unsupplemented crude lysates as compared to some
other approaches (Phizicky et al., 1995). These include i) its detection of the YB-1 cyclin D1 interaction in midst of all competing proteins present in the crude lysates, ii)
both the antigen and the interacting proteins are present in the same relative
concentrations found in the cells, iii) elaborate complexes involving YB-1 and cyclin D1
if present, are already in their natural state and can be readily co-precipitated and iv) the
two proteins are present in their natural state of posttranslational modifications. Therefore
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Fig. 3.14 YB-1 and Cyclin D1 show a change in distribution after actinomycin D
treatment
Indirect immunofluorescence analysis was done on control untreated and actinomycin D
treated transcriptionally blocked cells for 0-24 hrs. using antibodies against YB-1 (green)
and cyclin D1 (red). YB-1 was detected predominantly in the cytoplasm and cyclin D1 in
the nucleus in untreated cells (panel A). Decrease in levels of cyclin D1 was seen starting
at 30 min. time point of incubation (panel B) upto the 1 hr. time point (panel C) and by 2
hrs. it was seen co-localized with YB-1 predominantly in the cytoplasm (panel D). Cyclin
D1 was again detected in the nucleus starting at 4hrs. (panel E) and 8hrs. (panel F) time
points. Distribution of cyclin D1 was seen increasing in the nucleus by the 12 hrs. and 24
hrs. time periods of incubation (panels G and H).
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interactions that require for example phosphorylation, or the lack of it can more
realistically be assessed.
But there are also some disadvantages of using co-immunoprecipitation assays.
These include i) this assay system is not as sensitive as some other techniques like protein
affinity chromatography, because the concentration of the antigen is lower than it is in
protein affinity chromatography, ii) co-immunoprecipitation of YB-1 with cyclin D1 and
vice versa does not necessarily indicate that they interact directly, since they can be a part
of some larger complexes in the cell, like in case of E1A and cyclin A proteins (Harlow
et al., 1986; Ewen et al., 1992; Faha et al., 1992). In fact, we detected from our
preliminary experiments that both YB-1 and cyclin D1 immunoprecipitated with two
nuclear factor kappa B (NF-κB) subunits, namely p52 and Rel B. YB-1 was already
shown to interact with the NF-κB subunit p65 or Rel A, to modulate its interaction to
DNA (Raj et al., 1996). NF-κB was shown to be involved in transcriptional regulation of
cyclin D1 (Guttridge et al., 1999). However NF-κB independent activation of cyclin D1
by Rac was shown in MEFs (Klein et al., 2007). It is possible that the YB-1 - cyclin D1
interaction is mediated by the two NF-κB subunits and they are all part of a bigger
protein complex.
Co-localization gives evolutionary processes the opportunity to convert nonspecific binding interactions into interactions that have functional consequences (Kuriyan
et al., 2007). Protein-protein interactions help in recruiting cytoplasmic polypeptides to
activated receptors, directing their assembly into larger complexes and targeting them to
defined subcellular locations. Therefore it was imperative to see if the YB-1 and cyclin
D1 proteins colocalize in cells. YB-1 is predominantly localized in the cytoplasm, mainly
in the perinuclear space. Cellular stresses like hyperthermia (Stein et al 2001), UV
irradiation (Koike et al. 1997) and anti-cancer drugs result in partial translocation of
YB-1 protein from cytoplasm to nucleus. The nuclear localization of YB-1 protein was
shown to be an important prognostic marker for cancer (Shibahara et al. 2001). Cyclin
D1 is present in either nucleus or cytoplasm or both, depending on the phase of cell cycle
(Lukas et al., 1994; Diehl et al., 1998). But the mechanisms that regulate this periodic
subcellular redistribution of cyclin D1 during cell division cycle are not defined.
We detected co-localization between YB-1 and cyclin D1, especially in the
cytoplasm of G2/M phase blocked cells. This suggests the likelihood that interaction
between YB-1 and cyclin D1 takes place in vivo. Previous studies showed that there is
post-transcriptional induction in the levels of cyclin D1 during transition from the S to G2
phase in cell cycle (Yang et al., 2006) and the nuclear cyclin is translocated to the
cytoplasm during this transition (Sumrejkanchanakij et al., 2003), resulting in its
predominant cytoplasmic distribution. In order to rule out the possibility of predominant
immunoprecipitation of cyclin D1 with YB-1 and vice versa from G2/M phase cells due
to the physical presence of both proteins in high concentrations in the same subcellular
compartment, we analyzed the nuclear + cytoplasmic extracts of control cells, thereby
putting both proteins together in the same fraction. The fact that we do not detect
increased immunoprecipitation of YB-1 with cyclin D1 and vice versa in these cells
suggests that this interaction is not post lysis.
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The predominant distribution of cyclin D1 in the cytoplasm of G2/M phase
blocked cells and its co-localization with YB-1 can be attributed to many reasons. The
cytoplasmic cyclin D1 seen in the G2/M cells might be the product of export of the
nuclear cyclin D1 seen in the wild type and G1/S phase blocked cells into the cytoplasm.
However cyclin D1 has been reported to be a highly unstable protein with a half-life
ranging from 13 to 40 min. at the maximum, depending on the cell growth conditions and
the phase of cell cycle (Matsushime et al., 1991; Diehl et al., 1998). Besides cyclin D1 is
transported to the cytoplasm for proteolysis. So it is highly unlikely that the cytoplasmic
cyclin D1 seen is the product of nuclear export. Since cyclin D1 degradation by
polyubiquitination occurs in cytoplasm (Diehl et al., 1997; Alt et al., 2000), its absence
from the nucleus can be attributed to nuclear export for proteolysis, but the predominant
cytoplasmic cyclin D1 is not a result of this nuclear export. There is also a possibility that
the cytoplasmic cyclin D1 might be a combination of the newly synthesized and the preexisting cytoplasmic cyclin D1.
The cyclin D1 seen in the cytoplasm may be just the newly synthesized product
and YB-1 might play a role in maintaining this newly formed cyclin D1 in the cytoplasm.
From the literature, this seems to be the most likely explanation. Cyclin D1 is expressed
at low levels during the S-phase to allow sufficient DNA synthesis (Pagano et al., 1994)
but then induced to high levels in the G2 phase through Ras activity to commit the cells
to continuing the cell cycle progression (Sherr et al., 1992; Aktas et al., 1997; ConnelCrowley et al., 1998; Albercht et al., 1999; Hitomi et al., 1999). Cyclin D1 gets excluded
from the nucleus after the S-phase (Baldin et al., 1993; Guo et al., 2005) and this nuclear
export has been shown to be mediated by its phosphorylation by glycogen synthase
kinase-3β (GSK-3β), in association with nuclear exportin, CRM1 (Diehl et al., 1998; Alt
et al., 2000). Cyclin D1 lacks a nuclear localization signal and under the influence of
p21 Cip1 gets associated with CDK4 to get translocated to the nucleus (Alt et al., 2002)
and enter the nucleus only at the G1 phase (Baldin et al., 1993). There is a possibility that
YB-1 sequesters this cyclin D1 in the cytoplasm of G2/M phase cells.
In order to investigate if the N-terminus of YB-1 plays a role in its interaction with
cyclin D1, we relied on co-immunoprecipitation assays performed on cells incubated with
the four APGFP fusion proteins. We show immunoprecipitation of cyclin D1 with fusion
proteins APYB26GFP and APYB77GFP from G2/M phase blocked cells. Since cyclin
D1 gets immunoprecipitated only in cells incubated with APYB77GFP and
APYB26GFP, it is most likely that the AP rich sequence AAPPAAPALSAADTK,
missing from the clone APYB36GFP, is atleast atleast to a certain extent responsible for
mediating YB-1 binding to cyclin D1 either directly or indirectly. Cyclin D1 is
translocated to the cytoplasm during S/G2 transition and failure of re-entry of cyclin D1
into nucleus is known to block cells at the G2 phase of cell cycle. YB-1 is also found in
the cytoplasm at the G2 phase. Our current study shows that YB-1 predominantly binds
to cyclin D1 in the cytoplasm of G2/M phase cells. Our previous study as described in the
second chapter showed that ectopic introduction of APYB77GFP and APYB26GFP into
rat hepatoma cells led to G2/M phase cell cycle arrest and apoptosis. We suggest the
possibility that this interaction of cyclin D1 with the N-terminus of YB-1 results in its
sequestration in the cytoplasm of G2/M phase blocked cells. Cyclin D1 has been shown
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to be sequestered in the cytoplasm of cardiomyocytes and post mitotic neurons where its
activity might be regulated through cytoplasmic sequestration (Tamamori-Adachi et al.,
2003; Sumrejkanchanakij et al., 2003). Cyclin D1 interacts with CDK4/6 at all stages and
so should be able to translocate to the nucleus. The mechanism behind cytoplasmic
sequestration of cyclin D1 is not understood. We speculate that YB-1 binding to cyclin
D1 at this stage might result in its sequestration.
Co-immunoprecipitation of cyclin D1 is not seen in unsynchronized cells. This
difference can be attributed to spatial constraints resulting from the localization of both
proteins in different sub-cellular compartments in unsynchronized cells. Since the three
APYBGFP proteins are seen restricted to the cytoplasm and the cyclin D1 is
predominantly present in the nucleus of unsynchronized cells, minimal interaction of
cyclin D1 with APYBGFP would have been possible.
Posttranslational protein modifications, most notably phosphorylation, represent a
common mechanism through which signaling systems are controlled. This regulatory
device is inseparably linked with the physical interactions of signaling proteins, since
protein phosphorylation commonly exerts its effects by creating binding sites for a set of
protein interaction domains, whose ability to bind to their targets is phosphorylation
dependent. Phosphorylation can also be viewed as a device to control the assembly of
protein complexes and thereby to regulate the dynamic behavior of the cell. In order to
understand more about the nucleo-cytoplasmic shuttling of YB-1 and cyclin D1 seen
especially in the G2/M phase of cell cycle, we investigated if the phosphorylation states
of either of the proteins important for their interaction and/or co-localization with each
other.
We report that incubation of nocodazole blocked cells with wortmannin, which is a
pharmacological inhibitor of the PI3K-AkT pathway through which YB-1 is
phosphorylated, changes the localization pattern of cyclin D1. It has been shown that
unphosphorylated YB-1 translationally represses cyclin D1 mRNA (Evdokimova et al.,
2006) and once it is phosphorylated, it unbinds from the mRNA and thus cyclin D1
mRNA is free to get translated. According to the previous literature, protein levels of
cyclin D1 are maximal in the G2 phase of cells cycle (Guo et al., 2002) and this increase
is due to an increase in translational rate, as the transcription rate of cyclin D1 is steady at
the S/G2 phase (Guo et al., 2002). This and the fact that cyclin D1 half life is very short
led us to believe that it is most likely that the cytoplasmic cyclin D1 seen in nocodazole
blocked cells is newly synthesized. Therefore YB-1 is more likely than not in its
phosphorylated state. YB-1 is phosphorylated at its Ser102 position by the PI3K-AkT
pathway (Sutherland et al., 2005). This phosphorylation of YB-1 is totally inhibited by
incubation of cells with wortmannin (Evdokimova et al., 2006).
Simultaneous incubation of cells with nocodazole and wortmannin should block
the cells in G2/M phase as well as render the YB-1 unphosphorylated. We confirmed the
decrease in phosphorylated YB-1 in wortmannin blocked cells by immunoblotting
analysis of whole cell extracts with phospho-serine antibody (data not shown). Under
these conditions cyclin D1 was present in both cytoplasm and nucleus, as opposed to its
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predominant cytoplasmic presence in only nocodazole blocked cells. This suggests that
YB-1 phosphorylation is probably directly or indirectly important for the sub-cellular
localization of cyclin D1 at the G2/M phase of cell cycle. However, the PI3K pathway is
involved in regulating many downstream targets other than YB-1 like FKHR, mTOR,
p70S6K and Mdm2. Therefore we cannot conclude that YB-1 phosphorylation is indeed
directly responsible for the change in cyclin D1 distribution, but it is a strong possibility.
We can rule out the GSK-3β pathway involvement in this process since wortmannin
blocking of the PI3K phosphorylation pathway renders the GSK-3β active to transport
the cyclin D1 into the cytoplasm and yet cyclin D1 is still seen in the nucleus.
A block in cyclin D1 phosphorylation using LiCl did not change the pattern of
distribution of YB-1 or cyclin D1 after nocodazole block, suggesting that this interaction
might be independent of the phosphorylation state of cyclin D1. However, it has been
shown that cyclin D1 cytoplasmic export is dependent on its phosphorylation by GSK-3β
(Alt et al., 2000). But since cyclin D1 proteolysis cannot occur in nucleus, the most likely
explanation for its nuclear absence is nuclear export. Some studies have indeed
demonstrated that cyclin D1 ubiquitylation and its rapid degradation can occur
independently of GSK-3β under certain condition (Germain et al., 2000; Zou et al.,
2004). The previous literature and our results combined together suggest that there are
many more facets to cyclin D1 nuclear export and YB-1 - cyclin D1 interaction and
subcellular translocation is a possible step in this process.
In depth analysis of the importance of phosphorylation in YB-1 – cyclin D1
interaction has to be done to gain a better understanding. Previous studies have shown
that phosphorylation dependent protein-protein interactions can easily be studied using
yeast or bacterial two-hybrid systems (Guo et al., 2004; Shaywitz et al., 2002).
Quantitative proteomics techniques have been employed to obtain information regarding
phosphorylation status and signal dependent protein interactions in signal transduction
cascades (Patterson et al., 2003).
Since YB-1 and Cyclin D1 bind to the same sub-units of NF-κB complex, p52 and
Rel B and cyclin D1 has NF-κB binding site in its promoter region, there is a possibility
that YB-1 might be involved in indirect transcriptional regulation of cyclin D1 by this
binding with p52 and Rel B. Transcriptional block with actinomycin D showed a time
dependent change in localization pattern of YB-1 and cyclin D1. The results obtained can
be attributed to various possibilities including i) After actinomycin block the cells cannot
proceed with cell cycle and therefore get blocked most probably in G2/M phase, since
G2/M phase synchronized cells showed the same pattern of distribution of the two
proteins as seen till nearly the 4hrs. actinomycin block. ii) Since the cyclin D1 half-life is
quite short, most of the nuclear cyclin D1 is degraded by 30 min. to 1 hr. time points and
the cytoplasmic cyclin D1 seen may be the product of newly translated protein from preexisting mRNAs. iii) Cyclin D1 nuclear import is being prevented until nearly the 4-8hrs
time point that might potentially be caused by YB-1.
We propose the possibility that the YB-1 – cyclin D1 interaction is one of the
various mechanisms by which YB-1 is involved in mediation of cell proliferation. The
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final conclusion from this part of the project is that YB-1 interacts with cyclin D1 at the
G2/M phase and probably sequesters it in the cytoplasm, thereby regulating the cell
proliferation. We believe that targeting this interaction may help us in understanding the
role played by the upregulation of these proteins in the aberrant cells. It might eventually
help us to develop mechanisms to prevent their upregulation and thereby decrease the
proportion of cells undergoing tumorigenesis. Characterizing this specific complex seen
at all phases of cell cycle may offer novel strategies for the development of new anticancer drugs.
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Chapter 4. Summary and Overview
4.1

Summary

YB-1 expression is closely associated with cell proliferation; for example, YB-1 is
highly expressed in regenerating liver and liver cancers but barely detectable in normal
adult liver (Grant et al., 1993; Kandala et al., 1994). The domain/domains of YB-1
potentially involved in regulation of cell proliferation and the molecular mechanism
behind this regulation has not been described. Our previous study demonstrated that
disruption of one allele of Chk-YB-1b gene in DT-40 cells at its N-terminal domain
resulted in growth defects in the heterozygous mutants (Swamynathan et al., 2002). We
hypothesized that the abnormalities seen were due to a dominant negative effect exerted
by the putative truncated protein product of the disrupted allele.
The first goal of this project was to determine if the YB-1 N-terminus is involved
in regulation of cell proliferation by investigating whether the cell cycle defects in
heterozygous mutant DT-40 cells could be recapitulated by introducing YB-1 N-terminal
purified proteins into mammalian cell lines. We demonstrated that introduction of the
fusion proteins reproduced the G2/M phase block and apoptosis seen in the DT-40
mutants. These results confirm our hypothesis that the N-terminal domain of YB-1 is
involved in regulation of cell proliferation. The second part of the project was to
investigate the molecular mechanism behind this regulation of cell proliferation by YB-1.
Our study for the first time showed a protein-protein interaction between YB-1 and cyclin
D1 in the cytoplasm of cells in G2/M phase of cell cycle and we propose that this
interaction might be one of the molecular mechanisms behind the regulation of cell
proliferation by YB-1. These results are summarized in Fig 4.1.
4.2

Discussion

4.2.1 Potential YB-1 N-terminal sequences playing a role in cell proliferation
We tested the influence of three YB-1 N-terminal sequences on cell proliferation.
APYB77GFP incubation resulted in maximum G2/M phase cell cycle arrest and
apoptosis. APYB36GFP incubation showed the least effect. This variation could be due
to multiple reasons. One of the possibilities is that the proline alanine rich sequence in
APYB77GFP and APYB26GFP, which is absent from APYB36GFP, might be solely
responsible for this difference by its direct binding to some cell cycle protein.
Alternatively, this proline alanine rich sequence might aid in proper folding/unfolding
and configuration of the fusion proteins and the lack of it might result in a different three
dimensional structure of APYB36GFP, thereby rendering it less functional by either
hiding the sequence responsible for causing the defects or by some other mechanism.
Another possible explanation is that the sequences flanking the proline rich sequence
might also have a role to play in mediating these defects. Since APYB36GFP fusion
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Fig 4.1 Summary of the results of this study
We showed that the N-terminal domain of YB-1 plays a role in cell proliferation and
apoptosis. The YB-1 N-terminus is also involved in binding to the cell cycle protein
cyclin D1 in the cytoplasm of cells in G2/M phase of cell cycle.
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protein has some of the flanking sequences, it might show minimal defects in the cell
growth. There is also a possibility that the proline rich sequence might be functioning just
as a spacer between its flanking sequences in order for them to exert their effects and the
lack of this spacer in the APYB36GFP protein brings together two stretches of sequences
which might render lesser competency to aid in regulating cell proliferation. The
APYB26GFP incubation showing lesser effect on cell cycle than the APYB77GFP
suggests that the APYB26GFP lacks some amino acids required for maximal effect. The
APYB36GFP incubation resulting in significantly lesser effect, suggests that it has some
amino acids required for exerting this effect but lacks most of them. Therefore the most
likely explanation for this differential response would be that the proline rich sequence
along with some other amino acids, most likely the ones flanking this sequence, might be
mediating this YB-1 regulation of cell proliferation.
4.2.2 YB-1 N-terminus interacts with cyclin D1 in the cytoplasm of G2/M phase cells
We show interaction of YB-1 with cyclin D1 in the cytoplasm of G2/M phase
blocked cells. Further analysis with YB-1 N-terminal fusion proteins revealed that cyclin
D1 immunoprecipitated only with APYB77GFP or APYB26GFP from G2/M phase
blocked whole cell extracts, suggesting not only that the YB-1 N-terminus is involved in
the interaction, but also that the short proline alanine rich sequence AAPPAAPALSAADTK is crucial for this interaction. Since incubation with the same
two fusion proteins resulted in maximal cell cycle arrest and apoptosis, we suggest the
possibility that this proline alanine rich sequence binds and sequesters the cyclin D1 in
the cytoplasm of G2/M phase cells thereby rendering a block in the progression of cell
cycle. But lower proportion of G2/M phase arrested and apoptotic cells observed with
APYB26GFP compared to APYB77GFP suggests that the proposed cyclin D1 interaction
with the proline rich sequence is not solely involved in mediating this arrest. The other
amino acid residues present in the YB77 fusion protein but absent from the YB26 protein
might also have a role to play in this process.
4.3

Hypothesis

We propose that the binding of YB-1 N-terminal proline rich sequence with cyclin
D1 in the cytoplasm of G2/M phase cells, sequesters the cyclin D1 and restricts its reentry into the nucleus for cell cycle progression, resulting in an arrest at the G2/M phase
and apoptosis. We put forth a model (Fig. 4.2) to explain our hypothesis. In normal cells,
YB-1 regulates cyclin D1 tranlation by binding to its mRNA. External stimuli (step 1)
causing phosphorylation of YB-1 releases it from the cyclin D1 mRNA (step 2) which is
now free to be translated (Evdokimova et al., 2006). Once the cyclin D1 protein is formed
(step 3), it binds with CDK4/6 (step 4) for its nuclear entry (step 5). Nuclear cyclin D1
helps in cell cycle progression from the G1 to S phase (step 6), after which the cyclin D1
is excluded from the nucleus (step 8). Therefore during cell cycle transition from S to G2
phase, cyclin D1 is found in the cell cycoplasm. This cyclin D1 may be a product of the
nuclear export (step 8) and/or new translation (step 9). Simulation of the G2/M phase in
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Fig 4.2 Model of cyclin D1 sequestration by binding to YB-1 N-terminal proteins
in the cytoplasm of G2/M phase cells leading to cell cycle arrest
The model can be explained in different steps represented by numbers for simplification.
Unphosphorylated YB-1 binds and represses cyclin D1 mRNA translation. External
stimuli (1) activating the PI3K-AkT pathway causes YB-1 phosphorylation resulting in
release of the cyclin D1 mRNA (2). The new cyclin D1 protein interacts with CDK4/6 (3
and 4), translocates to the nucleus (6) and aids in G1 to S phase cell cycle progression
(6). Further progression of cell cycle to the G2/M phase requires cytoplasmic
translocation of cyclin D1(8). We simulated the G2/M phase in cells by a nocodazole
block (7). We propose that under conditions when the cell is targeted for apoptosis, the
YB-1 N-terminal proteins (10) bind to the cyclin D1 (11 and 12) and sequester them in
the cytoplasm (13), resulting in cell cycle arrest at the G2/M phase and ultimately
apoptosis (14).
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our cells with a nocodazole block (step 7), along with introduction of the YB-1 Nterminal proteins (step 10), resulted in cell cycle arrest and apoptosis (Figs. 2.13 to 2.16).
We propose that the YB-1 N-terminus binds with this cyclin D1 (steps 11 and 12) and
restricts its entry/re-entry into the nucleus (step 13), resulting in an arrest in cell cycle at
the G2/M phase and apoptosis (step 14). The broad idea behind this hypothesis is that
once the cell fate is determined, different pathways are activated (step 1) to prepare the
cell for either another round of division (steps 5 and 6) or cell cycle arrest (steps 8 to 14).
So when the cell has to continue cell division, N-terminus of YB-1 does not interact with
cyclin D1 (steps 11 and 12), which can then translocate to the nucleus for another round
of division (steps 4-6). But when the cells have to stop dividing, the YB-1 N-terminus
binds to cyclin D1 (step 11 and 12), sequestering it in the cytoplasm (step 13) and
arresting the cells at the G2/M phase of cell cycle (step 14), by hitherto unknown
mechanisms.
We also suspect that YB-1 regulates the cyclin D1 at both translational and posttranslational levels. Unphosphorylated YB-1 binds to cyclin D1 mRNA (Evdokimova et
al., 2006) in the cytoplasm and represses its translation. Once YB-1 is phosphorylated
(step 1), cyclin D1 translational block is released, new cyclin D1 protein is synthesized,
which binds with CDK4/6 to enter the nucleus and aid in cell cycle progression from G1
to S phase (steps 3 to 6), after which the cyclin D1 translocates to the cell cytoplasm (step
8). We saw from our experiments that under normal conditions, YB-1 and Cyclin D1
interaction was seen to be predominant in the cytoplasm of G2/M phase cells (Figs 3.4 to
3.6). But under a wortmannin block where YB-1 phosphorylation is inhibited, cyclin D1
is found in the nucleus at the G2/M phase (Fig. 3.8), suggesting the possibility of
phosphorylated YB-1 binding to the nuclear cyclin D1 to aid its cytoplasmic transport at
the G2/M phase. YB-1 is phosphorylated at the Ser102 position in its CSD domain by the
PI3K-AkT pathway (Sutherland et al., 2005), which is inhibited in this case by
wortmannin incubation (Evdokimova et al., 2006). So there is a possibility that through
different domains in its protein, YB-1 regulates the cell proliferation in different ways.
When the cell proliferation has to be controlled, its N-terminus interacts with the
cytoplasmic Cyclin D1 (step 11 and 12), restricting its nuclear entry, resulting in cell
cycle arrest. When cell proliferation has to continue, the N-terminus does not interact
with cyclin D1, but the CSD interacts with it in the nucleus for translocation into the
cytoplasm thereby helping in cell cycle progression, because a block in cytoplasmic
translocation of cyclin D1 results in cell cycle arrest at the G1/S phase. Thus YB-1 might
be post-translationally controlling the cyclin D1.
The total levels of YB-1 protein may also be playing a role in this differential
regulation of cell proliferation. High amounts of nuclear translocation of YB-1 have been
reported in actively proliferating and cancer cells (Jurchott et al., 2003; Oda et al., 2003;
Fujita et al., 2005). There is a possibility that this increase in nuclear YB-1 aids in the
cytoplasmic translocation of cyclin D1 at the S/G2 phase through its CSD, which helps in
progression of the cell cycle. In the absence of a stress or proliferative stimuli, most of
the cellular YB-1 is cytoplasmic, where its N-terminus can interact with Cyclin D1 in
order to control the levels of cell proliferation. We propose that the molecular mechanism
behind regulation of cell proliferation by YB-1 involves this complex regulation of
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translational and post translational levels of cyclin D1 and its nucleocytoplasmic
transport through binding with YB-1 mediated by its N-terminus and cold shock domain.
4.4

Future experiments to test our hypothesis

Testing our hypothesis about cytoplasmic sequestration of cyclin D1 by YB-1 in
the G2/M phase during a nocodazole block is relatively easy, because of its reversibility
by incubating the blocked cells in a nocodazole free medium for about 24 hrs. So if the
YB-1 N-terminal sequence does sequester the cyclin D1 in cell cytoplasm resulting in an
arrest at the G2/M phase, removal of the nocodazole from the incubation medium should
not decrease the cell cycle arrest and apoptosis of the cells. The cyclin D1 should still get
immunoprecipitated with APYB77GFP and APYB26GFP.
A way of testing if interaction of the N-terminal YB-1 proteins with cyclin D1
results in cell cycle arrest is to supplement the cells with increasing concentrations of
proteins competing for binding with either YB-1 (example p53) or cyclin D1 (example
CDK4/6). If the dose dependent increase in competing proteins immunoprecipitating
YB-1 or cyclin D1 results in an decrease of immunoprecipitation of cyclin D1 with either
of the N-terminal YB-1 proteins, resulting in comparable decrease in the cell cycle arrest
and apoptosis, it would suggest that the defects seen are indeed due to the interaction
between YB-1 N-terminal proteins with cyclin D1. Our results and this hypothesis is in
agreement with some previously published studies, showing that Cyclin D1 cytoplasmic
sequestration results in cell cycle arrest at the G2/M phase (Alao et al., 2006). The
mechanism behind cytoplasmic sequestration of cyclin D1 has not been understood and
our data provides a new avenue for further exploration of the possibility of the Nterminus of YB-1 causing this sequestration.
But even if the YB-1 N-terminal proteins do sequester cyclin D1 in the cell
cytoplasm resulting in the cell cycle arrest, the proline rich sequence might not
necessarily be involved in this interaction. This sequence might only be important for
protein folding or separating the two flanking sequences. The importance of these
sequences can be checked by constructing fusion proteins with i) only the proline rich
sequence, ii) only the sequences flanking this proline rich sequence and iii) the flanking
sequences along with the a random spacer sequence instead of the proline rich sequence.
Structural analysis of the APYBGFP fusion proteins might also give us a fair idea of the
importance of this proline rich sequence in protein folding and the residues which are
exposed in each of the fusion proteins for taking part in protein-protein interactions.
We have a custom peptide constituting of only the 26 proline-alanine rich amino
acids present in APYB26GFP. This peptide can be exploited for i) investigating if this
sequence is enough for interaction with cyclin D1. Peptide bound beads can be used for
affinity chromatography of whole cell extracts followed by proteomic analysis, in order
to investigate if cyclin D1 gets immunoprecipitated with this sequence. This procedure
will also enable identification of any other proteins, which bind with the proline alanine
rich sequence. Differential bindings can also be analyzed by using different sub-cellular
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extracts or extracts prepared after various treatments. ii) After the binding assays, this
peptide can also be used to investigate if cytoplasmic cyclin D1 sequestration is seen by
its introduction into cells. If the YB-1 proline rich sequence interacts with and sequesters
cyclin D1 in the cell cytoplasm resulting in cell cycle arrest, introduction of this peptide
should result in ultimate apoptosis. iii) This peptide can also to be used as a competing
protein for binding of the cytoplasmic cyclin D1 with APYB77GFP or APYB26GFP. If
indeed this sequence is sufficient for binding with cyclin D1, the competitive assay
should reduce the levels of cyclin D1 pull down with the GFP antibody from
APYB77GFP or APYB26GFP incubated cells, while still maintaining similar levels of
cell cycle arrest and apoptosis. iv) We can also explore the possibility of complimenting
the peptide positive cells with a fusion protein missing this exact sequence, in order to
test the importance of the 77 amino acid YB-1 N-terminal sequence in inducing cell cycle
arrest and apoptosis.
From our localization analysis of YB-1 and cyclin D1 under wortmannin and LiCl
incubations, we had proposed the possibility of phosphorylated YB-1 being important for
the predominant cytoplasmic cyclin D1 localization in G2/M phase. This possibility can
be tested by using an YB-1 CSD Ser102 mutant for similar localization analysis. YB-1 is
phosphorylated by the PI3K-AkT pathway at this position and this phosphorylation is
completely inhibited by wortmannin. If YB-1 phosphorylation is important for cyclin D1
cytoplasmic localization at the G2/M phase, use of this mutant protein should not result
in predominant cytoplasmic cyclin D1 at the G2/M phase. Since this experiment does not
involve the use of wortmannin, we can rule out the possibility of other pathways (which
are downstream to the PI3K-AkT) being involved in this process. The caveat of this
experiment would be the presence of endogenous wild type YB-1. This can be overcome
by initial downregulation of the wild type YB-1 protein by using siRNA specific for
either the N-terminus or the C-terminus of YB-1 so that it does not affect our mutant
protein. This experiment will extend our understanding of the interaction of YB-1 with
cyclin D1.
If we can confirm that the phosphorylation state of YB-1 is important for cyclin D1
cytoplasmic localization in G2/M phase cells from this experiment, we can look into the
future possibility of testing the hypothesis of the YB-1 CSD domain interacting with
cyclin D1 for its nuclear export and the YB-1 N-terminal domain interacting with it for
cytoplasmic sequestration. The experimental design to test this hypothesis can involve the
use of YB-1 deletion mutants expressing i) wild type CSD domain, ii) wild type amino
and CSD domains, iii) CSD Ser102 mutant, iv) wild type amino domain and the CSD
Ser102 mutant, v) full length YB-1 with just the Ser102 mutant along with the wild type
full length protein.
4.5

Significance - YB-1 and cancer

YB-1 protein levels are highly upregulated in actively proliferating cells including
cancer cells. Numerous studies have also shown that nuclear accumulation of YB-1 is a
good predictor of cancer (Bargou et al., 1997; Oda et al., 1998 and 2003; Kamura et al.,
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1999; Shibahara et al., 2001; Yahata et al., 2002; Saji et al., 2003; Gessner et al., 2004;
Yasen et al., 2005; Fujita et al., 2005; Basaki et al., 2007). Therefore it seems likely that
there is significant nuclear accumulation of YB-1 during uncontrolled cell proliferation
and predominant cytoplasmic localization in other conditions including apoptotic cells.
But we do not know as yet if this increase in proteins in cancer cells is due to increased
YB-1 translation or increase in amounts of YB-1 mRNA. Many studies have targeted
YB-1 in order to find novel approaches to cancer therapy, albeit with little success. Most
recently, some preclinical studies targeted YB-1 in order to develop therapeutic strategies
against breast cancer (Fujii et al., 2008). Many prior studies have also shown or indicated
importance of similar targeting of YB-1 for various cancer treatments with limited
success (Kamura et al., 1999; Janz et al., 2002; Holm et al, 2004; Huang et al., 2005;
Mantwill et al., 2006; Vaiman et al., 2007; Stratford et al., 2007). In absence of the
knowledge of the exact molecular mechanism, it is difficult to design therapeutic agents
against YB-1 for cancer treatment.
The first half of this project was designed to investigate the involvement of the
N-terminal domain in an attempt to make targeting of YB-1 for cancer therapy more
specific. The second half of this project was designed to broaden the scope of targeting
YB-1 for cancer therapy by investigating the association of YB-1 with the cell cycle
protein cyclin D1 at specific stages in cell cycle. We found that the N-terminus of YB-1
plays a role in cell proliferation. With this information, further experiments can be
designed to investigate if increase in levels of the YB-1 N-terminal proteins in other
cancer cells results in a decrease in cell proliferation or increase in cell cycle arrest
thereby ultimately aiding in cancer regression. Our study also suggests that the small
proline alanine rich sequence (PPAAPPAAPALSAADTK) from the YB-1 N-terminus
might be important for the regulation of cell proliferation by YB-1. We also show that
this sequence is a strong potential candidate for interaction of YB-1 with cyclin D1 in the
cytoplasm of cells in G2/M phase of cell cycle, which might result in the sequestration of
cyclin D1 resulting in cell cycle arrest. Analysis of the important of this sequence could
pave a definite road into understanding the minimal YB-1 N-terminal sequence required
for its involvement in cell proliferation. If further exprements can prove that the cell
cycle arrest is indeed due to cytoplasmic sequestration of cyclin D1, this information can
be further exploited for use in cancer therapy in association with YB-1 or even
independent of YB-1. Therefore the data from this project extends our understanding of
the role of YB-1 in cell proliferation in terms of the specific YB-1 domain mediating this
process and a very strong potential mechanism by which it is mediated.
4.6 Future directions
Based on the results of this project, future studies can focus on i) importance of
YB-1 N-terminal protein binding to cyclin D1 in the cytoplasm of G2/M phase cells in
terms of its cytoplasmic sequestration, ii) importance of the non proline rich YB-1
N-terminal sequence in cell proliferation, iii) investigating if the YB-1 CSD is also
involved in interaction with cyclin D1 and iv) investigation of the importance of YB-1
Ser102 phosphorylation for its interaction with cyclin D1 and the nucleocytoplasmic
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shuttling of cyclin D1. It might also be interesting to investigate if YB-1 and Cyclin D1
are a part of a larger protein complex consisting of NF-κB subunits Rel B and p52 and if
YB-1 is involved in the indirect transcription regulation of cyclin D1 gene in association
with NF-κB. Ultimately, investigating the importance of YB-1 in cell proliferation will
benefit our understanding of how and why it is upregulated in cancer cells.
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